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ABSTRACT
Occupational Risk Factors in Chronic Obstructive Pulmonary Disease
Brent C. Doney
Introduction: Chronic obstructive pulmonary disease (COPD) causes increased disability and
mortality in the U.S. population. Approximately 15% of cases of COPD can be attributed to
occupational exposure. There are gaps in the knowledge of the relationships between
occupational exposure and COPD and further investigation can provide information helpful in
improving COPD preventive strategies in the workplace. The objective of this project was to
assess COPD prevalence in population based studies and characterize the relationship between
COPD and occupational exposure.
Methods/Results: Three separate U.S. population-based cross-sectional studies of COPD were
conducted. In the first study, a COPD job exposure matrix (JEM) was created to characterize
exposure of working adults to vapors-gas, dust, and fumes (VGDF). Next the JEM was applied
to investigate the association between occupational exposure and COPD using data from a large
population-based study where good quality spirometry and questionnaire data on chronic
bronchitis, wheeze, and severity and duration of exposure to VGDF were collected. In the
second study, COPD prevalence was estimated for the older U.S. population (40–79 years of
age) over two periods, years 1988–1994 and years 2007–2010. The results show that COPD
prevalence is declining. However, COPD still remains a significant problem. In the third study,
prevalence estimates of COPD for the U.S. working population by major occupational groups
were estimated. Higher odds of COPD were found among certain occupation groups.
Conclusions: The findings from this study provide perspective on contemporary trends in
COPD prevalence and confirm that COPD remains a substantial problem in the U.S. population
and more specifically in the working population. Exposure to VGDF continues to be associated
with COPD as does smoking. This research expands the evidence on the association of COPD
with VGDF exposure and certain occupation groups highlighting current trends in the U.S.
occupations at risk for COPD. Understanding these evolving trends in COPD prevalence helps
to develop strategies and interventions to further reduce exposure to VGDF and tobacco smoking
to reduce the burden of COPD.
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Chapter 1
Introduction
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Chapter 1
1.1

Introduction
Chronic obstructive pulmonary disease (COPD) is a disease with broad public health

implications. COPD is estimated to cause about 3 million deaths globally per year (1). A more
complete understanding of the risk factors associated with COPD and populations afflicted by
the disease will help to guide and improve intervention strategies to prevent COPD. Tobacco
smoking is strongly associated with COPD and the estimated population attributable risk due to
tobacco smoking is approximately 80% (2). In addition, inhalation of aerosolized particles,
gases, and/or vapors in the workplace is also known to be associated with increased risk of
COPD. A strategic priority goal of the National Institute for Occupational Safety and Health
(NIOSH) is to conduct research and provide guidelines to prevent and reduce COPD at
workplace (3). This study contributed to the understanding of the role of occupation and
smoking as risk factors for COPD in the U.S. population.
There are several important definitions developed by the American Thoracic Society (4)
for the diagnosis and understanding of COPD and are quoted in this paragraph. COPD is a
preventable and treatable disease state characterized by airflow obstruction that is not fully
reversible. Airflow obstruction is usually progressive and is associated with an abnormal
inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette
smoking. There are two underlying pathological conditions, which may be present in COPD:
first, chronic bronchitis which is clinically defined as a chronic productive cough for 3 months in
each of 2 successive years in a patient in whom other causes of productive cough have been
excluded; second, emphysema which is pathologically defined as the presence of permanent
enlargement of the airspaces distal to the terminal bronchioles accompanied by destruction of
their walls, and without obvious fibrosis.
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Research of COPD in this project focused on several health outcomes that define COPD.
In two of our studies COPD was defined by abnormally low level of lung function or airflow
obstruction determined by using spirometric measurements. The results from individual
spirometry tests were compared to reference lung function values of healthy never smokers of
similar age, gender, race, and height. If the observed lung function value fell below the lower
limit of normal (LLN), a person would be classified as having airflow obstruction. LLN
approximates the one-sided 95% confidence limit for the expected value, where 5% of healthy
persons who have never smoked would be identified as abnormal (4). In addition, COPD was
identified through questionnaires by asking the participant about healthcare provider diagnosed
chronic bronchitis or emphysema.
The focus of the current study was to investigate the prevalence of the various COPD
outcomes in several cross-sectional studies and estimate their association with occupational risk
factors such as vapors-gas, dust or fumes (VGDF), or the association with occupational
categories. An additional focus of our study was to develop and test a job exposure matrix for
COPD outcomes based on reported job and industry where a study participant worked. The
results of this study are intended to provide information to guide NIOSH to address its strategic
priority goal to improve intervention strategies to prevent development of COPD associated with
workplace exposures. In addition, the information will help NIOSH stakeholders and the
broader international occupational health community to develop intervention strategies based on
our publications in peer reviewed journals.
1.1.1

Prevalence and Costs of COPD
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and

mortality globally according to the World Health Organization (WHO). COPD causes
approximately 3 million deaths annually, and this number is projected to increase for years (1).
3

In the U.S., an estimated 15.0 million people had physician diagnosed COPD in 2010 and
12.0 million had undiagnosed COPD. COPD ranks third in causes of mortality resulting in
approximately 100,000 deaths annually (5–7). The National Heart, Lung, and Blood Institute
estimated the total annual cost of COPD for 2010 as $49.9 billion (8). The COPD associated
disability also reduces the probability of being employed by 8.6% (7).
COPD is a chronic disease which usually develops and is more prevalent among older
adults (9, 10). Therefore for the three studies, data for adults starting at either age 40 or 45 were
analyzed.
1.1.2

Occupational Risk Factors and Their Contribution to COPD
The American Thoracic Society stated that approximately 15% of COPD cases in the

general population of the developed countries are attributable to occupational risk factors (11,
12). A more recent study of the general U.S. population estimated the overall fraction of COPD
attributable to work exposure as 19% overall and 31% among never smokers (13). To prevent
work-related COPD, occupational risk factors should be identified, including types of industries,
occupations, and specific types of exposures that increase the risk of COPD in the working
population.
Epidemiological studies help to improve our knowledge of occupational risk factors and
the literature reflects studies identifying various workplace risk factors associated with COPD.
Hedrick (14) concluded that certain occupations are likely to increase the risk of COPD and that
there are probably interactions between smoking and exposures that make the effect worse.
Blanc and Toren (15) from their review of the literature concluded that there is a causal
association between work-related exposure and COPD. They summarized occupational risks
(exposure) of the 14 studies from 2000 through 2006 with endpoints of either COPD or chronic
bronchitis evaluated through questionnaire or spirometry. Significant associations were found
4

with exposures to dust, fumes, mineral dust, dusty trades, biological dust, and among laborers
and by occupation.
The role of biological agents in questionnaire ascertained chronic bronchitis and
spirometry ascertained COPD among farmers was investigated by Eduard et al. (16). Exposures
were measured on the Norwegian farms and the odds of either chronic bronchitis or COPD were
significantly higher with increased concentrations of total dust, organic dust, spores, inorganic
dust and silica.
Exposure to dust in coal and hard-rock miners is associated with increased severity of
emphysema (11). Hnizdo found a combined effect of smoking and dust exposure on COPD
among gold miners (17). Blanc, Menezes et al. (18) found an association between dusty trades
and COPD for males and females throughout the world. Trupin et al. (19) reported that people
with a COPD or chronic bronchitis diagnosis were two times more likely to report a past work
exposure to gases, dusts, vapors, or fumes. Bergdahl et al. (20) found an increased risk of
construction worker mortality from COPD from any airborne exposure or to inorganic dust and
the hazard ratio doubled among never smokers.
Blanc et al. (21) created an overall COPD job exposure matrix (JEM) and applied it to
their Kaiser case-control study. They found significantly higher odds of COPD with high
exposure to VGDF as assessed by the JEM.
1.2

Gap in the Literature

Although much is known about the risk factor of smoking and its relationship with COPD (4,
22), less is known about the occupational risk factors including VGDF. The creation of a job
exposure matrix specific for COPD helped to improve our understanding of the association
between COPD and VGDF exposure and also current trends in COPD by occupation and
exposure as work conditions evolve in the U.S. Population-based studies can collect information
5

about exposure through either self-reported exposure in a questionnaire or by providing
information about the industry and occupation where participants worked. Because there are
usually no direct measurements of occupational exposure in population-based studies, JEMs
have been developed to assign a level of potential exposure to study participants, based on their
reported occupation. The JEM is designed to assign an exposure score reflecting the potential
agents and level of potential exposure for each occupational category defined by a standardized
three digit occupational code. The occupational information from studies can then be coded into
the standardized occupational codes and matched with the COPD JEM to help in our
understanding of the COPD risk in relation to the VGDF exposure (21, 23). Another method of
assessment of the risk of COPD in relation to the VGDF exposure is to compare the odds of
COPD in each occupational group with a reference group. Both this method and the JEM
method were employed in this project to help to fill the literature gap. Our project is linked with
the Healthy People 2020 Respiratory Diseases, Chronic Obstruction Pulmonary Disease
objectives RD-10 (to reduce deaths) and RD-11 (to reduce hospitalizations) from COPD among
adults (24).
1.3

Purpose of the Current Research
Because the potential occupational risk factors for COPD are varied, it is important to

investigate their effect using various industry or population-based studies. Our long-range goal
is to understand the risk factors for COPD to provide information for COPD prevention. The
objective of this study is to identify and characterize the risk factors for COPD. The central
hypothesis is that COPD is associated with occupational risk factors including exposure to
VGDF and with smoking. The hypothesis has been formulated by a review of the literature (18,
21, 25–31) and an investigation of COPD associations in another study population (32, 33). The
rationale for the proposed study is to identify the risk factors for COPD. It will also build on past
6

research efforts to update and refine previous research findings and knowledge regarding risk
factors for COPD. This will provide a more clears contemporary understanding of risk factors to
help aid prevention.
Gaps in the knowledge of COPD risk factors and the contribution of occupational
exposure to COPD are explored through three specific aims. The three aims are investigated
through the three studies presented in Chapters 2, 3, and 4 using secondary data analysis of
quantitative data obtained from population-based cross-sectional studies. The first aim (Chapter
2) was to create and test a JEM for COPD using data from the Multi-Ethnic Study of
Atherosclerosis (MESA) lung study. The JEM was created by an industrial hygienist and a
consensus was reached by three industrial hygienists to reflect the typical agents and severity of
exposures in each occupation to ascertain occupational exposure scores. The exposure scores
included an overall VGDF score and more specific exposure scores for dust, organic dust,
mineral dust, gas-vapors, and fumes. The second aim (Chapter 2) was to determine if
occupational exposure to VGDF is a risk factor for COPD. The associations between
occupational exposures and COPD were determined using either the JEM or self-reported VGDF
exposure ascertained by questionnaire in this MESA cohort. COPD was determined by
spirometry (pulmonary function test) or by self-report of healthcare provider diagnosis of chronic
bronchitis.
The third aim was to determine the prevalence and trend of COPD using two national
studies of the U.S. population. The first study (Chapter 3) used data from a national study of the
U.S. population (National Health and Nutrition Examination Surveys (NHANES)) which
incorporated spirometry defined airflow obstruction to compare COPD prevalence between two
sampling periods 1988–1994 and 2007–2010. We estimated prevalence of COPD for the 40–79
year old population. The second study (Chapter 4) used data from a national study of the U.S.
population (National Health Interview Survey (NHIS)) which incorporated self-reported doctor7

diagnosed chronic bronchitis or emphysema defined COPD for years 2004–2011. We estimated
prevalence and prevalence odds ratios (POR) for COPD for major occupational groups among
the 40–70 year old working population.
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Chapter 2
Occupational Risk Factors for COPD Phenotypes in the Multi-Ethnic Study
of Atherosclerosis (MESA) Lung Study
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2.1

Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that

is not fully reversible, is usually progressive and associated with inflammatory response to
noxious particles and gasses (1). COPD is one of the leading causes of morbidity and mortality
worldwide. According to the World Health Organization, COPD affects approximately 65
million people worldwide and is responsible for approximately 3 million deaths annually. This
prevalence and associated mortality is projected to increase, and by 2030 COPD is expected to
be the third leading cause of death (2, 3). In the U.S. in 2009, there were 137 082 deaths from
chronic lower respiratory disease (primarily COPD), the third leading cause of mortality (4, 5).
The American Thoracic Society (ATS) estimated that approximately 15% of COPD in
the general population is attributable to occupational sources (6). The estimated cost of
occupational COPD in the U.S. in 1996 was approximately $5 billion (7). The estimated fraction
of COPD attributable to work exposure in the U.S. population is 19% overall and 31% among
never smokers (8). Several recent population-based studies show associations between COPD
and occupational risk factors, which include vapor-gas, dust, and fume (VGDF) exposure (9–15).
Few of these studies, however, have included a large number of U.S. minority groups that may
be at increased risk (16).
The aim of this study is to further identify and characterize occupational risk factors for
COPD in an older, multiethnic U.S. sample using a newly developed job exposure matrix (JEM)
and questionnaire ascertained exposure. Specifically, we aim to evaluate whether occupational
exposure to VGDF as ascertained by a questionnaire and JEM are risk factors for airflow
limitation, chronic bronchitis and wheeze.
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2.2

Methods

2.2.1

Study Population
The Multi-Ethnic Study of Atherosclerosis (MESA) recruited a population-based sample

of participants 45-84 years old that were free of clinical cardiovascular disease in 2000-2002
from six predominantly large urban U.S. communities located in California, Illinois, Maryland,
Minnesota, New York, and North Carolina. The participation rate was 60% among those
screened and deemed eligible (17). The four race/ethnicity groups in this analysis were White,
Black, Chinese, and Hispanic.
The MESA Lung Study enrolled MESA participants that were sampled from those that
underwent baseline measurements of endothelial function, consented to genetic analyses, and
underwent an examination during the MESA Lung Study recruitment period between 2004 and
2006 (Figure 2.1) (18).
2.2.2

Occupational Exposure Assessment
We used two methods of occupational exposure assessment: (1) responses to questions on

exposure to VGDF; and (2) JEM for the assessment of COPD risk constructed by NIOSH
industrial hygienists. The JEM made use of the self-reported current occupation and industry if
employed or the occupation where last employed if retired (ascertained using questions, see
Appendix for pertinent excerpts from the questionnaires). The reported industry and occupation
were coded by trained staff from the National Institute for Occupational Safety and Health
(NIOSH) into U.S. Census 2000 occupation and industry coding.
2.2.3

Construction of the NIOSH JEM
To construct a generalizable JEM, we used the University of California San Francisco

(UCSF) JEM Census occupational codes and added the additional MESA Census occupational
codes not available in the UCSF JEM (9). An industrial hygienist then constructed the NIOSH
JEM by assigning an exposure score (1, 2, or 3) representing the likelihood of the presence and
15

severity of the VGDF exposure (low, medium, and high) for each Census occupation code based
on expert opinion. In addition, the method of exposure coding applied in the Weinmann et al.
(14) study was adopted for assigning the exposure scores in this study (19). The hygienist
similarly created separate scores representing the likelihood and severity of exposure to vaporgas, fumes, dust, and subcategories of dust (mineral; organic). Two certified industrial
hygienists then reviewed and discussed the preliminary JEM scores and assigned a final
consensus score. Environmental tobacco smoke was considered in the overall VGDF score for
occupations with likely exposure (e.g., bartenders and waitresses), although a separate exposure
score was not assigned.
2.2.4

Spirometry, Airflow Limitation, and Respiratory Symptoms and Diseases
Spirometry tests were conducted in 2004–2006 in accordance with the ATS/European

Respiratory Society (ERS) guidelines (20) and all participants attempted at least three acceptable
maneuvers. Tests were conducted using a dry-rolling-seal spirometer and software that
performed automated quality checks as maneuvers were performed (Occupational Marketing,
Inc., Houston, TX). All spirometry exams were reviewed by one investigator and each test was
graded for quality; participants with no acceptable curves were excluded (21). All participants
that completed an acceptable spirometry test and had industry and occupation data (n=3686)
were included in this study.
Airflow limitation was defined as the ratio of forced expiratory volume in one second to
forced vital capacity (FEV1/ FVC) below the lower limit of normal (LLN) and FEV1 < LLN (22).
NHANES-based reference equations (23) were used to estimate the LLN values, however, for
Asian-Americans, a correction factor of 0.88 was applied to calculate the LLN for FEV1 (21).
The Hankinson reference equations including the correction factors for Asian-Americans have
been previously validated using MESA data (21).
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The other health outcomes investigated were symptoms of chronic bronchitis, wheeze,
and self-reported physician-diagnosed “chronic obstructive pulmonary disease or COPD...or
emphysema.” Chronic bronchitis (Medical Research Council) was defined as 3 or more months
of chronic productive cough per year in 2 or more years (Appendix). Wheeze was defined by the
question, “In the last 12 months, have you had wheezing or whistling in your chest?”
The National Heart, Lung, and Blood Institute (NHLBI) funded the MESA study and the
ancillary MESA Lung Study; the JEM coding was funded by the National Institute for
Occupational Safety and Health (NIOSH). The MESA study protocol was approved by the
Institutional Review Board in each field center and the NHLBI; the current analysis was
approved by the Institutional Review Board of NIOSH. Written informed consent was obtained
from each participant.
2.2.5

Data Analysis
A logistic regression model was used to estimate the association between occupational

risk factors and the dichotomous variable of airflow limitation. The occupational risk was
evaluated using self-reported exposure and exposure established using the NIOSH JEM. The
occupational exposure variables individually evaluated in the logistic model included selfreported exposures to vapor-gas, dust, fumes; severity of VGDF exposure, years of exposure to
VGDF, and exposure scores assigned by the JEM. An additional variable (number of VGDF
agents) was created to reflect the number of agents (i.e., vapor-gas, dust, and/or fumes) to which
the person reported exposure (none, one, two, or three). The covariates adjusted for in the model
were age, gender, race/ethnicity, education, body mass index (BMI), smoking status, pack-years,
cigar-years, pipe-years, environmental tobacco smoke, and asthma. BMI was divided into four
categories: < 25, 25 – <30, 30 – <35, and ≥ 35 kg/m2 to reflect the potential effect of BMI on
lung function (24). Since there were few participants with BMI<18 these were combined into the
<25 category. In addition, separate models for never smokers were evaluated.
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To investigate the combined effect of the occupational exposure and smoking on the
various health outcomes, we created interaction variables combining smoking status (ever/never)
and occupational exposure status [i.e., self-reported exposure (yes/no) or JEM (no=low,
yes=medium or high) for dust, vapor-gas, and fumes, and VGDF]. The data were then analyzed
using a model with three dummy variables comparing those with occupational exposure only,
smoking only, and both smoking and occupational exposure to those without any of the two
exposures, to determine a trend in the odds ratios. In addition, to test the interaction effect on a
multiplicative scale, we included in the logistic model occupational exposure, smoking, and the
interaction term (9, 10).
2.3

Results
Demographic data for age, race/ethnicity, smoking status, BMI, and education are

presented in Table 2.1. There were 3667 individuals with spirometry and complete information
used in this analysis out of 3686 included in the occupational sample (Figure 2.1). The study
sample was 36% non-Hispanic White, 26% African-American, 22% Hispanic and 16% ChineseAmerican, and 44% had never smoked cigarettes. Table 2.1 shows the characteristics of the
sample overall, stratified by race/ethnicity, and restricted to never smokers (45%). A large
proportion had education beyond high school (66.7%) and 44.3% were employed in the
management or professional occupational group while 19.3% were blue-collar workers. The
prevalence of moderate airflow limitation (FEV1/FVC < LLN and FEV1 < LLN) was 5.7%
overall, 6.7% for males, 4.7% for females, and 2.1% among never smokers.
Frequencies of occupational exposures as ascertained by a questionnaire and by the job
exposure matrix are also presented in Table 2.1. For all participants, 37.9% self-reported
exposure to dust, 19.4% to vapor-gas, and 24.2% to fumes, and 13.7% and 5.2% reported
moderate and severe VGDF exposure, respectively. According to the JEM, the medium and high
exposures totaled 12.0% for dust (5.3% for mineral dust, 7.6% for organic dust), 17.6% for
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vapor-gas, 4.6% for fumes, and the overall medium to high VGDF exposure was 15.1%. The
proportion who were retired at the time of spirometry was 41.6%.
The adjusted odds ratios for the associations of airflow limitation with occupational
exposure, in the whole cohort, show significant associations with self-reported vapor-gas
exposure (Table 2.2). The dose-responses for severity of exposure and for the number of
exposures reached statistical significance at the highest categories. The number of cases was,
however, too small to perform meaningful analysis using race/ethnic stratification.
Among never-smokers, airflow limitation was associated with the highest severity of selfreported exposure to VGDF with the odds ratio almost seven times that of “All” participants
(Table 2.2). Among never-smokers, there was also an increasing trend in the odds of airflow
limitation as the number of self-reported VGDF agents (exposure to 0, 1, 2, or 3 agents)
increased, P < 0.01, with exposure to three agents associated with five times higher odds of
airflow limitation (OR 5.1, 95% CI 1.5–16.7). Additionally, never-smokers exposed to VGDF
for 15 or more years had over triple the odds of airflow limitation (OR 3.3, 95% CI 1.3–8.7).
Also among never-smokers, the odds of airflow limitation was more than doubled with selfreported exposure to vapor-gas (OR 2.7, 95% CI 1.1–6.7) and increased 4-fold with exposure to
fumes (OR 4.2, 95% CI 1.7–9.9) in comparison to those not exposed.
For associations with exposure to dusts as ascertained by the JEM, the odds ratios for
airflow limitation doubled for highest level of exposure, especially among males, and nearly
tripled for organic dust exposure among females (Table 2.2). We did not find significant
association between airflow limitation and the JEM VGDF score (results not shown). There was
a low Spearman rank correlation (0.21, P<0.001) between self-report of VGDF and the JEM
VGDF. Figure 2.2 shows the odds ratios for self-reported specific exposures (vapor-gas, dust,
fumes) and the severity of exposure to VGDF and airflow limitation.
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Odds ratios for the associations between airflow limitation and the combined effect of
smoking and each of the occupational exposures are reported in Table 2.3. For all the specific
exposures to vapor-gas, dust, fumes, and general VGDF exposure there was an increasing trend
in the odds ratios, including for the category with both exposures present. However, none of the
odds ratios for the interaction effect were statistically significant at p<0.05 level, rejecting the
hypothesis that there is multiplicative interaction. The combined associations were similar for
males and females.
Self-reported doctor-diagnosed COPD associations reached statistical significance with
self-reported dust exposure among “All” participants (OR 1.7, 95% CI 1.0–2.6), vapor-gas
among “All” participants (OR 2.0, 95% CI 1.2–3.3), especially among females, and self-reported
years of exposure to VGDF for 1-15 and over 15 years (Table 2.4). COPD also was associated
with self-reported exposure to all three VGDF agents among “All” participants (OR 2.6, 95% CI
1.4–5.0), among females (OR 6.0, 95% CI 1.9–19.2), and among never-smokers (OR 14.2, 95%
CI 2.1–94.9). COPD was associated with severity of exposure, especially in the highest severity
category (OR 2.8, 95% CI 1.3–6.1).
Chronic bronchitis was associated with self-reported dust, vapor-gas, fumes, severity of
exposure, years of exposure and the number of VGDF agents (Table 2.5, Figure 2.2), but not
with the JEM exposure scores. Likewise, wheeze was associated with self-reported dust, vaporgas, fumes, severity of exposure, years of exposure, and the number of VGDF agents (Table 2.5,
Figure 2.2), but not with the JEM exposure scores.
For chronic bronchitis, the combined effect of smoking and self-reported VGDF exposure
or JEM assigned VGDF exposure was evaluated in a manner similar to airflow limitation.
Similarly, for all the exposures (vapor-gas, dust, fumes, and VGDF) there was an increasing
trend in the odds ratios, including for the category with both exposures present (results not
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shown). However, none of the odds ratios for the interaction effect were statistically significant
at p<0.05 level, rejecting the hypothesis that there is multiplicative interaction.
2.4 Discussion
We found that airflow limitation, physician-diagnosed COPD, chronic bronchitis, and
wheeze were associated with self-reported occupational exposure to vapors, gas, dust and fumes
in a large, multi-ethnic study of participants 45 to 84 years of age when initially recruited during
2000–2002. Associations were particularly strong among never smokers and for the severity of
exposure. This study adds to our understanding about the association of VGDF exposure with
non-malignant respiratory conditions and about the two methods of ascertainment of
occupational exposure: self-reported using a questionnaire and a JEM.
We found that airflow limitation was associated with JEM-assigned scores for VGDF,
dust and organic dust. To compare results for self-reported dust exposure with those for JEMassigned dust exposure (low, medium, or high), the self-reported exposure had elevated odds
while with the JEM the highest assigned dust category was significant (Table 2.2). The
increased risk associated with highest JEM dust exposure category was primarily in males. This
result may suggest that the JEM’s three levels of exposure categorization may better capture the
highest exposure level while the dichotomous self-reported dust exposure cannot differentiate the
exposure levels.
Using the JEM, we also investigated the association of airflow limitation with exposure
to organic dust for which we did not have self-reported data, and found that for “All” participants
there was an increasing trend for airflow limitation across the level of exposure (i.e., low,
medium, and high) (X2 = 3.8, P = 0.05). The association was statistically significant in females.
This indicates that the JEM method may be useful also in the evaluation of occupational
exposures for which self-report data are not available.
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Among never-smokers (Table 2.2), associations with airflow limitation were observed for
self-reported severity of VGDF exposure, the number of self-reported agents, and number of
years exposed to VGDF agents. These findings are consistent with a study reported by Blanc et
al. (9) where self-reported VGDF and JEM assigned VGDF exposure were found to be
associated with COPD. However, in our study we did not find a significant association between
airflow limitation and the JEM VGDF. The low Spearman rank correlation between selfreported VGDF and the JEM VGDF may indicate that the participants’ own knowledge of their
exposure was better than the JEM when the information about the longest held job was not
available.
Self-reported doctor-diagnosed COPD was associated with self-reported dust, vapor-gas,
number of years of exposure to VGDF, increasing severity of exposure to VGDF, and increasing
number of agents (Table 2.4). Some of the odds of COPD were increased 2-fold or greater
among never-smokers. This result is consistent with a study by Blanc et al. (9).
Chronic bronchitis is a major component of COPD; therefore Medical Research Council
(MRC)-defined chronic bronchitis as determined by several questions was evaluated for
association with occupational exposure (Appendix). Chronic bronchitis was associated with selfreported occupational exposure to dust, vapor-gas, fumes, severity of exposure to VGDF, years
of exposure to VGDF, and with the increasing number of agents (none, one, two, or three) of
vapor-gas, dust, and/or fumes (Table 2.5). This result reinforces the well-known association
between occupational exposure and “industrial bronchitis” (15, 25-27). We also investigated the
association of chronic bronchitis with the combined effect of smoking and each exposure. The
results (not tabulated) were similar to those for airflow limitation.
Wheeze is a symptom often associated with airflow limitation (28, 29). In our study,
wheeze within the last year was associated with occupational exposures to vapor-gas, dust,
fumes, a progressive gradient of severity of exposure to VGDF, and with the increased number
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of the VGDF agents reported by participants. These associations were also consistent by gender
and among never smokers (Table 2.5). The associations of chronic bronchitis and wheeze with
occupational exposure were stronger than with airflow limitation.
This study has some limitations, which are: 1) temporality cannot be determined; 2)
questionnaire data pertaining to past occupational exposure may be prone to recall bias in that
respondents with disease or symptoms may have considered the presence and more severe
exposure than respondents without symptoms. The use of both questionnaire self-reported
exposure and JEMs should help reduce potential for misclassification bias (9, 30, 31). Since
participants may not be aware that they have airflow limitation, differential misclassification
would be less likely for this outcome than for reported symptoms of chronic bronchitis and
wheezing. 3) For some outcomes, the highest JEM exposure category had insufficient sample
size to determine a significant trend. 4) Another important limitation is that the JEM assessment
was based on the most recent job. Almost 42% of the MESA-Lung participants were retired at
the time of spirometry and only the most recent job prior to retirement was reported. This lack
of information on the longest held job may have decreased concordance between the JEM and
self-reported exposure and reduced the ability of the JEM to detect the effects of occupational
exposure on disease.
The MESA study was designed prospectively to study subclinical factors for
cardiovascular disease (CVD) and thus individuals with existing clinical CVD were excluded at
the onset of the study (17). CVD is one of the conditions that occur with the highest COPD
comorbidity (32–34). This exclusion may have introduced a survivor bias among elderly
participants; yet, it is unlikely to have affected participants under 65 years. When investigating
the prevalence of airflow limitation and self-report of severity, the sensitivity analysis results for
the most severe category were similar for those under 65 years (n=2133) and those over 65 years
(n=1375) (OR 1.8, 95% CI 0.9–3.6 vs. OR 2.2, 95% CI 0.9–5.8). Therefore, with respect to
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airflow limitation, survivor bias appears to be less likely in this population. However, Sin et al.
reported that reduced FEV1 is a risk for cardiovascular mortality; therefore excluding those with
cardiovascular disease may also exclude individuals with reduced FEV1 and COPD in this study
resulting in reduced odds ratios for airflow limitation (32).
2.5

Conclusion
We found significant associations between the prevalence of airflow limitation and

occupational exposure ascertained by both self-report and JEM. We did not find an association
between COPD and the combined effect of occupational exposure and smoking on the
multiplicative scale, but there was an indication of an increased risk of COPD when both
exposures were present. We developed an expanded COPD JEM based on the methodology of a
previously developed JEM for use in future occupational studies. Chronic bronchitis and wheeze
each were associated with self-reported exposures (vapor-gas, dust, fumes, and VGDF exposure
severity, years of exposure, and number of agents). Smoking cessation programs combined with
the reduction of occupational exposures should be pursued to reduce the prevalence of COPD in
workers.

Abbreviations
CI

confidence interval

MESA

Multi-Ethnic Study of Atherosclerosis

JEM

job exposure matrix

UCSF

University of California San Francisco

FEV1

forced expiratory volume in one second

FEV1/ FVC ratio of forced expiratory volume in one second to forced vital capacity
LLN

lower limit of normal – the LLN approximates the one-sided 95% confidence
limit for the expected value, where 5% of healthy persons who have never
smoked would be identified as abnormal using the LLN
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MRC

Medical Research Council
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2.7

Appendix: Pertinent Questions from Questionnaires
A trained interviewer administered a Respiratory Questionnaire to the MESA-Lung

participants. Information from the MESA-Lung study in this analysis was supplemented through
other MESA questionnaires where participants were asked to identify race/ethnicity using the
2000 Census questions. The respondents were then categorized into one of four racial/ethnic
groups.
The script provided to the interviewers for the question was extracted from page 13 of the
“MESA-Lung field Center Manual of Operations and Procedures Version 1.9 April 8, 2005. The
interviewers were instructed to read every question EXACTLY as written, including the
responses. For clarification, they were instructed to re-read the question and answers for the
participant. If the participant had questions regarding the definitions for the three questions, they
were only allowed to provide the definitions in the “Note” section. The number of times
(interviews) that the note for the questions was used was not captured.
The occupational exposure was determined by the following questions:
Q.13. Have you ever been exposed at work to:
(This is “ever” exposure, and it does not have to be daily exposure).
Vapors or gas Answer “yes” or “no” or “don’t know”.
Note: vapors are really synonymous with gas, that is the form into which liquids are
naturally converted by the action of a sufficient degree of heat.
Dust Answer “yes” or “no” or “don’t know”.
Note: dust is fine particulate matter which is light enough to be to be easily raised and
carried up into the air.
Fumes Answer “yes” or “no” or “don’t know”.
Note: fumes are volatile matter produced by and usually accompanying combustion
(where there’s smoke, there’s fumes -- although the converse is not completely true).
If yes to any of the above, answer the following:
For how many years were you exposed at work to vapors, gas, dust or fumes?
Provide the number of years. ___ years
How long ago was your last exposure?
Select “current” or provide the number in months OR in years.
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____ current OR ___ months OR ____years
Was the exposure “mild” or moderate” or severe’? ___ mild ___ moderate ___severe
Select one. Note that the exposure is in order of increasing level.
Wheezing was determined by the following question:
In the last 12 months, have you had wheezing or whistling in your chest?
Yes
No
Asthma was determined by the following question:
Have you ever had asthma?
Yes
No
COPD was determined by emphysema questions and the following question:
Has a doctor ever told you that you had any of the following:
Chronic obstructive pulmonary disease or COPD?
Yes
No
Don’
t know
MRC Bronchitis is based on cough and phlegm questions from the spirometry
questionnaire:

“Do you usually bring up phlegm from your chest on most days for 3 or more months during
the year?”
“For how many years have you brought up phlegm from your chest like this?”
“Do you usually have cough on most days for 3 or more months during the year?”
If respondent has a cough on most days for 3 or more months during the year, usually brings up
phlegm from chest on most days for 3 or more months during the year and did this for 2 or more
years, it was considered MRC Bronchitis.
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Emphysema was based on the Medical History interview administered questionnaires from
Exam 1 – 4. During Exam 1, the interviewer asked, “Has a doctor ever told you that you have
any of the following;
Q.1 Emphysema?”
Yes
No
Don’
t know
During Exams 2 – 4, the interviewer asked,
Q.2 Has a doctor told you that you have developed any of the following since your last MESA
visit on____: Emphysema?
Yes
No
Don’
t know

The occupation was determined by the following four open-ended questions from the
survey:
Q.9 For whom do/did you work? (name of company, business, organization or other employer)
If you are not working now, please respond regarding your main occupation before you stopped
working.
Q.10 What type of business or industry is/was this? (e.g., hospital, newspaper publishing, mail
order house, auto repair shop, bank, etc.)
Q.11 What kind of work do/did you do or what was your job title? (e.g. registered nurse,
personnel manager, auto mechanic, accountant, grinder operator, etc.)
Q.12 What are/were your most important activities or duties? (e.g. patient care, directing hiring
policies, repairing automobiles, reviewing financial records, operating grinding mill, etc.)
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Table 2.1. Characteristics of participants in the MESA Lung Study and occupational exposure as ascertained by
questionnaire and NIOSH job-exposure matrix (JEM)
Characteristic
All
Males
Females
Never-smokers

Age, mean (SD)
Race/ethnicity, %
White
Chinese
Black
Hispanic
Smoking status, %
Never
Former
Current
Cigarette pack-years, mean (SD)
Pipe-years, mean (SD)
Cigar-years, mean (SD)
Height (cm), mean (SD)
Weight (kg), mean (SD)
Body mass index, %
<25
25-<30
30-<35
≥35
Environmental Tobacco Smoke
Do not live with adult smoker
Live <21 years with adult smoker
Live ≥21 years with adult smoker
Education, %
Less than high school diploma
High school diploma
Some college/tech school
Bachelor’s degree or higher
Occupational group, %
Management/professional
Service
Sales and office
Blue-collar
Moderate airflow limitation, %
Asthma, self-report, %
COPD, self-report doctor diagnosed
(emphysema or COPD), %
Chronic bronchitis,† %
Wheeze in last year, self-report, %
Dust, %
Vapor-gas, %
Fumes, %
Severity, %
None
Mild
Moderate
Severe
No. of VGDF agents‡
0
1
2
3
Years exposure VGDF, %
None
≤15
>15

n=3667
61.1 (9.8)

n=1878
61.4 (9.9)

n=1789
60.7 (9.7)

n=1605
60.5 (9.9)

36.1
15.5
26.4
22.1

36.2
16.7
25.2
22.0

36.0
14.2
27.6
22.2

31.9
23.1
22.7
22.3

45.1
45.2
9.8
12.5 (22.6)
3.8 (26.1)
3.1 (23.7)
166.3 (9.9)
78.7 (17.1)

34.0
55.8
10.2
16.1 (25.5)
7.4 (36.1)
5.7 (31.8)
172.9 (7.5)
83.6 (15.7)

56.6
34.2
9.3
8.8 (18.4)
0.0 (0.6)
0.3 (8.6)
159.5 (7.2)
73.4 (17.1)

100.0
-----164.3 (9.9)
75.7 (16.6)

30.2
39.5
20.3
10.0

28.5
45.6
20.3
5.6

31.9
33.1
20.4
14.7

34.5
37.9
18.9
8.7

57.8
30.1
12.1

66.7
25.7
7.6

48.5
34.6
16.9

66.6
22.1
11.3

15.4
17.9
28.3
38.4

14.8
15.5
26.6
43.2

16.2
20.5
30.0
33.4

15.3
18.0
25.4
41.4

44.3
15.5
20.8
19.3
5.7
11.6
2.9

46.9
12.9
14.0
26.2
6.7
9.1
3.3

41.6
18.3
28.0
12.2
4.7
14.2
2.5

46.0
16.2
21.4
16.4
2.1
11.3
0.8

8.0
13.9
37.9
19.4
24.2

8.1
12.4
41.9
26.1
30.5

7.9
15.5
33.8
12.3
17.7

5.7
9.9
32.7
15.3
18.4

55.7
25.5
13.7
5.2

51.5
28.5
14.3
5.7

60.0
22.3
13.1
4.6

61.4
23.1
11.7
3.8

55.6
21.0
10.0
13.4

51.5
18.4
10.8
19.4

60.0
23.8
9.1
7.0

61.3
20.8
8.4
9.5

56.2
21.9
22.0

51.8
22.6
25.6

60.7
21.1
18.2

62.0
19.1
18.9
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Dust JEM, %
Low
88.0
83.2
93.1
Medium
9.2
11.9
6.3
High
2.8
4.9
0.6
VGDF JEM, %
Low
85.0
78.3
91.9
Medium
9.8
14.0
5.4
High
5.3
7.7
2.7
†
Medical Research Council (MRC) defined chronic bronchitis.
‡The number of VGDF agent was determined by exposure to gas/vapor, dust, and/or fumes.
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90.6
7.4
2.1
87.7
8.5
3.8

Table 2.2. Adjusted Odds Ratios (OR) for the association of airflow limitation† with occupational exposures
ascertained using questionnaire and NIOSH job-exposure matrix (JEM)
Exposure
All
Males
Females
Never-smokers
n=3508; airflow
n=1782; airflow
n=1726; airflow
n=1581; airflow
limitation=196
limitation=115
limitation=81
limitation=32
OR (95% CI)
1.23 (0.88–1.72)
1.55 (1.06–2.26)
1.39 (0.97–1.99)

OR (95% CI)
1.21 (0.77–1.90)
1.55 (0.97–2.47)
1.47 (0.93–2.32)

OR (95% CI)
1.23 (0.74–2.06)
1.36 (0.70– 2.65)
1.28 (0.71–2.33)

OR (95% CI)
1.98 (0.88–4.49)
2.71 (1.09–6.71)
4.15 (1.74–9.87)

1.0
1.18 (0.79–1.75)
1.48 (0.94–2.34)
2.13 (1.21–3.74)
7.5, p < 0.01

1.0
1.24 (0.74–2.08)
1.22 (0.65–2.31)
1.57 (0.72–3.46)
1.3, p = 0.25

1.0
1.09 (0.58–2.06)
1.82 (0.92–3.61)
2.99 (1.29–6.93)
7.0, p < 0.01

1.0
1.64 (0.57–4.72)
2.64 (0.85–8.20)
14.75 (4.06–53.63)
13.9, p < 0.001

1.31 (0.88–1.94)
1.31 (0.88–1.94)
2.0, p = 0.16

1.60 (0.95–2.71)
1.10 (0.64–1.91)
0.3, p = 0.60

0.98 (0.51–1.86)
1.63 (0.91–2.95)
2.3, p = 0.13

2.42 (0.90–6.52)
3.31 (1.26–8.69)
6.2, p < 0.05

1.0
1.40 (0.93–2.11)
1.40 (0.81–2.40)
1.69 (1.06–2.70)
5.1, p < 0.05

1.0
1.28 (0.71–2.32)
1.45 (0.71–2.98)
1.62 (0.91–2.88)
2.9, p = 0.09

1.0
1.54 (0.87–2.73)
1.35 (0.57–3.19)
1.53 (0.63–3.68)
1.4, p = 0.23

1.0
1.82 (0.63–5.22)
3.64 (1.12–11.92)
5.07 (1.54–16.69)
8.8, p < 0.01

1.0
1.08 (0.60–1.94)
2.35 (1.10–5.04)
3.3, p = 0.07

1.0
0.85 (0.40–1.81)
2.28 (1.03–5.07)
2.3, p = 0.13

1.0
1.80 (0.69–4.74)
-1.0, p = 0.32

1.0
1.99 (0.49– 8.11)
1.87 (0.16–21.66)
0.89, p = 0.34

Low

1.0

1.0

1.0

1.0

Medium

1.39 (0.70–2.77)

0.83 (0.31–2.20)

2.87 (1.05–7.87)

3.04 (0.67–13.69)

High

2.31 (0.93–5.74)

2.23 (0.87–5.76)

--

--

X2-trend, p-value

3.8, p = 0.05

1.5, p = 0.21

3.3, p = 0.07

0.4, p = 0.53

Dust
Vapor-gas
Fumes
Severity of VGDF
None
Mild
Moderate
Severe
X2-trend, p-value
Years exposure VGDF,
%
None
≤15
>15
X2-trend, p-value
No. of VGDF agents‡
0
1
2
3
X2-trend, p-value
Dust JEM
Low
Med
High
X2- trend, p-value
Organic dust JEM

†Odds ratios for airflow limitation adjusted for age, race/ethnicity, gender, BMI, smoking status, cigarette
pack-years, pipe-years, cigar-years, environmental tobacco smoke, asthma, and education.
‡The number of VGDF agent was determined by exposure to gas/vapor, dust, and/or fumes.
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Table 2.3. Adjusted Odds Ratios (OR) for association of airflow limitation† with the interaction of smoking
and occupational exposures from questionnaire and NIOSH job-exposure matrix (JEM)
Interaction association
All
Males
Females
n=3511; airflow
limitation=196

n=1785; airflow
limitation=115

n=1726; airflow
limitation=81

OR (95% CI)
OR (95% CI)
OR (95% CI)
Smoking/dust‡
Never/no
1.0
1.0
1.0
Never/yes
1.73 (0.84–3.56)
1.40 (0.43–4.59)
2.12 (0.84–5.34)
Ever/no
4.57 (2.62–7.96)
4.65 (1.91–11.28)
5.08 (2.39–10.81)
Ever/yes
5.47 (3.07–9.76)
5.97 (2.42–14.68)
5.15 (2.28–11.66)
Smoking/vapor-gas
Never/no
1.0
1.0
1.0
Never/yes
2.14 (0.97–4.72)
2.07 (0.62–6.98)
2.33 (0.78–6.94)
Ever/no
4.37 (2.71–7.05)
5.03 (2.23–11.34)
4.36 (2.33–8.15)
Ever/yes
6.10 (3.46–10.77)
7.43 (3.10–17.82)
4.52 (1.83–11.15)
Smoking/fumes
Never/no
1.0
1.0
1.0
Never/yes
3.00 (1.44–6.27)
2.82 (0.86–9.31)
3.58 (1.35–9.49)
Ever/no
5.30 (3.15–8.92)
5.99 (2.50–14.34)
5.54 (2.77–11.08)
Ever/yes
6.30 (3.52–11.30)
8.00 (3.19–20.04)
5.02 (2.09–12.08)
Smoking/any VGDF*
Never/no
1.0
1.0
1.0
Never/yes
2.47 (1.20–5.12)
2.63 (0.78–8.86)
2.59 (1.02–6.60)
Ever/no
5.09 (2.70–9.61)
5.92 (2.04–17.17)
5.31 (2.28–12.33)
Ever/yes
6.97 (3.68–13.20)
8.21 (2.83–23.85)
6.71 (2.86–15.78)
Smoking/ JEM-dust
Never/no
1.0
1.0
1.0
Never/yes
1.39 (0.39–4.88)
-3.33 (0.85–12.98)
Ever/no
3.94 (2.57–6.03)
4.16 (2.14–8.08)
4.00 (2.23–7.15)
Ever/yes
4.83 (2.61–8.96)
5.13 (2.26–11.64)
3.77 (0.99–14.30)
Smoking/ JEM-vapor-gas
Never/no
1.0
1.0
1.0
Never/yes
0.46 (0.11–2.03)
0.48 (0.06–3.93)
0.54 (0.07–4.40)
Ever/no
3.44 (2.26–5.23)
3.94 (2.01–7.73)
3.47 (1.98–6.09)
Ever/yes
3.15 (1.76–5.64)
3.78 (1.69–8.46)
1.81 (0.54–6.02)
†Odds ratios for airflow limitation adjusted for age, race/ethnicity, BMI, asthma, and education.
‡Smoking was ever (former or current) or never.
*Exposure was dichotomized into any of the agents (Vapor-gas, Dust and/or Fumes).
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Table 2.4. Adjusted Odds Ratios for Self-reported Physician Diagnosis of COPD,† with occupational exposure from questionnaire
Characteristic
All
Males
Females
Never-smokers
n=3508; COPD = 98

n=1758; COPD = 55

n=1701; COPD = 42

n=1581; COPD = 12

OR

OR

OR

OR

95% CI

95% CI

95% CI

95% CI

Dust
1.65
1.04–2.63
1.63 0.87–3.07
1.81 0.88–3.72
4.61
1.17–18.17
Vapor-gas
1.96
1.18–3.27
1.36 0.72–2.58
3.36 1.41–8.01
2.90
0.70–12.07
Fumes
1.44
0.87–2.36
0.93 0.49–1.78
2.92 1.31–6.50
6.25
1.37–28.57
Severity of VGDF
None
1.0
1.0
1.0
1.0
Mild
1.96
1.15–3.33
1.42 0.69–2.91
3.18 1.39–7.26
2.14
0.44–10.32
Moderate
1.93
1.01–3.67
1.17 0.47–2.94
3.58 1.37–9.36
1.60
0.17–14.95
Severe
2.80
1.29–6.09
3.05 1.22–7.61
1.25 0.23–6.74
15.19 1.92–120.5
X2-trend, p-value
8.8, p < 0.01
3.7, p = 0.05
4.1, p < 0.05
4.7, p = 0.03
Years exposure VGDF
None
1.0
1.0
1.0
1.0
≤15
2.17
1.26–3.74
1.64 0.79– 3.40
3.27 1.37– 7.83
3.46
0.85– 14.07
>15
1.84
1.06–3.17
1.54 0.74– 3.18
2.38 1.00– 5.65
1.86
0.31– 10.97
X2-trend, p-value
5.6, p < 0.05
1.5, p = 0.22
5.0, p < 0.05
1.3, p = 0.26
No. of VGDF agents‡
0
1.0
1.0
1.0
1.0
1
2.31
1.34–3.96
2.04 0.96–4.32
2.73 1.21–6.17
1.38
0.25–7.66
2
1.31
0.59–2.90
0.95 0.33–2.75
2.11 0.61–7.32
2.90
0.28–29.98
3
2.59
1.35–4.98
1.68 0.75–3.79
6.00 1.88–19.20
14.22 2.13–94.88
X2-trend, p-value
7.0, p < 0.01
0.9, p = 0.34
9.1, p < 0.01
6.5, p = 0.01
†
Odds ratios for self-reported physician diagnosis of COPD or emphysema adjusted for age, race/ethnicity, BMI, smoking status, cigarette
pack-years, pipe-years, cigar-years, environmental tobacco smoke, asthma, and education.
‡The number of VGDF agent was determined by exposure to vapor-gas, dust, and/or fumes.
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Table 2.5. Adjusted Odds Ratios for chronic bronchitis† and wheeze‡ with occupational exposure from questionnaire
Characteristic
All
Males
Females
Never smokers
Chronic bronchitis

n=3508;
chronic bronchitis = 280
OR
95% CI

n=1782; chronic
bronchitis = 143
OR
95% CI

n=1726; chronic
bronchitis = 137
OR
95% CI

n=1581; chronic
bronchitis = 91
OR
95% CI

Dust
Vapor-gas
Fumes
Severity of VGDF
None
Mild
Moderate
Severe
X2-trend, p-value
Years exposure VGDF
None
≤15
>15
X2-trend, p-value
No. of VGDF agents*
0
1
2
3
X2-trend, p-value

1.95
1.54
1.66

2.45
1.87
1.81

1.60
1.11
1.46

1.96
1.33
1.39

Wheeze

1.49–2.55
1.13–2.09
1.25–2.20

1.66–3.61
1.28–2.75
1.24–2.65

1.09–2.33
0.65–1.91
0.95–2.26

1.23–3.12
0.75–2.38
0.82–2.38

1.0
1.83
1.35–2.48
2.04
1.42–2.93
1.70
1.00–2.88
14.7, p < 0.001

1.0
2.14
1.38–3.30
2.73
1.65–4.53
1.25
0.54–2.89
8.1, p < 0.01

1.0
1.58
1.02–2.44
1.48
0.87–2.54
2.38
1.17–4.84
6.8, p < 0.01

1.0
1.12
0.63–1.98
2.25
1.23–4.13
3.38
1.43–7.97
10.8, p = 0.001

1.0
1.57
1.13–2.17
2.23
1.63–3.03
22.9, p < 0.0001

1.0
1.77
1.11–2.82
2.52
1.61–3.94
16.6, p < 0.0001

1.0
1.36
0.86–2.16
2.05
1.32–3.19
10.1, p < 0.01

1.0
1.23
0.69–2.19
1.81
1.04–3.13
5.4, p < 0.05

1.0
1.58
1.14–2.20
2.41
1.64–3.56
2.15
1.47–3.15
22.9, p < 0.0001

1.0
1.38
0.81–2.35
2.85
1.67–4.87
2.53
1.57–4.08
18.6, p < 0.001

1.0
1.71
1.11–2.63
1.91
1.07–3.41
1.57
0.79–3.14
5.1, p < 0.05

1.0
1.48
0.85–2.60
1.56
0.73–3.30
2.09
1.04–4.18
4.8, p < 0.05

n=3508; wheeze = 488
OR
95% CI
1.76
1.43–2.18
1.62
1.26–2.07
1.53
1.21–1.92

n=1783; wheeze = 219
OR
(95% CI)
2.13
1.54–2.95
1.65
1.20–2.28
1.60
1.16–2.21

n=1726; wheeze = 269
OR
(95% CI)
1.56
1.17–2.08
1.52
1.03–2.23
1.43
1.02–2.01

n=1564; wheeze = 156
OR
(95% CI)
1.83
1.28–2.63
1.32
0.84–2.08
1.64
1.09–2.47

Dust
Vapor-gas
Fumes
Severity of VGDF
None
1.0
1.0
1.0
1.0
Mild
1.67
1.30–2.14
2.0
1.37–2.90 1.46
1.04–2.04
1.39
0.90–2.13
Moderate
1.95
1.45–2.61
2.61
1.69–4.03 1.54
1.02–2.32
1.98
1.20–3.27
Severe
3.15
2.16–4.60
3.03
1.75–5.26 3.52
2.04–6.07
4.55
2.35–8.81
X2-trend, p-value
44.6, p < 0.0001
25.5, p < 0.0001
18.9, p < 0.0001
20.6, p < 0.0001
Years exposure VGDF
None
1.0
1.0
1.0
1.0
≤15
1.97
1.54–2.53
2.60
1.79–3.79 1.51
1.07–2.13
1.72
1.09–2.70
>15
1.92
1.48–2.48
1.93
1.31–2.85 2.04
1.44–2.90
1.55
0.97–2.48
X2-trend, p-value
28.9, p < 0.0001
12.5, p < 0.0001
16.9, p< 0.0001
8.2, p < 0.01
No. of VGDF agents*
0
1.0
1.0
1.0
1.0
1
1.84
1.42–2.37
2.23
1.47–3.37 1.62
1.16–2.25
1.72
1.12–2.63
2
1.75
1.25–2.45
2.09
1.28–3.41 1.52
0.95–2.45
1.66
0.92–2.97
3
2.14
1.57–2.90
2.41
1.60–3.63 1.92
1.17–3.16
2.11
1.22–3.67
X2-trend, p-value
27.2, p < 0.0001
17.3, p < 0.0001
9.5, p < 0.01
8.8, p < 0.01
†
Odds ratios for MRC defined chronic bronchitis adjusted for age, race/ethnicity, BMI, smoking status, cigarette pack-years,
pipe-years, cigar-years, environmental tobacco smoke, and education.
‡Odds ratios for wheeze in last 12 months adjusted for age, race/ethnicity, BMI, smoking status, cigarette pack-years,
pipe-years, cigar-years, environmental tobacco smoke, and education.
*The number of VGDF agent was determined by exposure to vapor-gas, dust, and/or fumes.
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6,814 Enrolled into
MESA
610 No Flow mediated dilation measure
196 No consent for genetic analysis
5,921 MESA pool from
which MESA-Lung was
selected

87 Lost to follow-up (dropped out/died)

760 Not selected based on race/ethnicity
breakdown requirements
5,161 Selected for
MESA-Lung
677 Did not attend MESA examination during
MESA-Lung recruitment
4,484 Eligible
519 Did not enroll

3,965 Enrolled into
MESA-Lung

13 Enrolled before spirometry exam began
20 Could not perform Spirometry

3,893 with
i

39 Refused spirometry

t
37 Had unusable spirometry

3,856 with valid
spirometry measures
170 missing Exam 1 industry and occupation
data
3,686 included in
occupation analysis
Figure 2.1. Algorithm of recruitment and exclusions for the MESA Lung Study occupational
analysis.
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Airflow Limitation
Figure 2. Adjusted Odds Ratios for airflow limitation, chronic bronchitis, wheeze
Chronic Bronchitis Chronic Bron chitis

Airflow Limitation

Chronic Bronchitis

Wheeze

Figure 2.2. Adjusted Odds Ratios for airflow limitation, chronic bronchitis,
wheeze and self-reported exposures.
†Severity is the most severe exposure to VGDF
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Chapter 3
Prevalence of Airflow Obstruction in U.S. Adults Aged 40–79 Years:
NHANES Data 1988–1994 and 2007–2010
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3.1

Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and

mortality worldwide (1). In the U.S., an estimated 15.0 million people had doctor-diagnosed
COPD in 2010 and 12.0 million had undiagnosed COPD. COPD ranks third in causes of
mortality resulting in about 100,000 deaths annually (2– 4). COPD is a costly disease; direct and
indirect healthcare costs are higher among COPD patients when compared to other patients. In a
case-control study, COPD patients used 50–60% more medical services (inpatient, emergency
department and office visits) than controls (5). The National Heart, Lung, and Blood Institute
estimated the total annual cost of COPD for 2010 to be $49.9 billion (6). COPD associated
disability also reduces the probability of being employed by 8.6% (3). Despite the decreased
prevalence of smoking over the last several decades (7, 8), a recent study reported that there was
little change in the overall prevalence of COPD among 20–79 year olds between the periods
1988–1994 and 2007–2010 using the NHANES pre-bronchodilator (pre-BD) spirometry data
based mainly on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (9)
to define COPD (10).
Spirometry measurements of the forced expiratory volume in the first second (FEV1) and
the FEV1 to forced vital capacity (FVC) ratio are recommended for the diagnosis of COPD and
for the study of COPD prevalence (11). The interpretation of the ratio differs, however,
depending on what professional recommendations are used. The American Thoracic Society
(ATS) recommends that a FEV1/FVC ratio below the lower 5th percentile (the lower limit of
normal, or LLN) as determined from a representative sample of healthy non-smokers, be used to
define airflow obstruction (12). The Global Initiative for Chronic Obstructive Lung Disease
(GOLD) (9, 13) recommends that post-bronchodilator (post-BD) spirometry with a ratio of
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FEV1/FVC below 0.7 be used to identify COPD (14). Several studies have shown that the
GOLD criteria can potentially over-diagnose COPD prevalence and over-estimate the COPD
burden in older adults, especially if pre-BD spirometry is used for the determination (15–18).
Since COPD is a costly disease, it is important to ensure that the estimates of the COPD
prevalence and burden in the current U.S. population are consistent and reliable to assure
sufficient planning and funding for prevention, treatment, and research.
The aim of our study was to evaluate changes in the prevalence of airflow obstruction
among older adults (40–79 years) for two periods of the NHANES study 1988–1994 and 2007–
2010. In contrast to the Ford et al. study (10), our focus is on using the ATS criteria to define
airflow obstruction. Since we applied the NHANES III reference equations in the determination
of the presence of airflow obstruction, we also tested how well the NHANES III (1988–1994)
equations fit the 2007–2010 data for healthy non-smokers to assess reliability of the estimates.
To determine the potential effect of using pre-BD spirometry on the estimation of the prevalence
of COPD, rather than post-BD spirometry as recommended by GOLD, we also evaluated the
change in the COPD GOLD Stage I and II status when using pre-BD and post-BD spirometry in
the NHANES participants who had both tests.
3.2

Methods
The National Center for Health Statistics of the Centers for Disease Control and

Prevention conducts the NHANES, which is a cross-sectional survey of the civilian, noninstitutionalized U.S. population (19). Household interviews and standardized physical
examinations [in mobile exam centers (MEC)] are used to collect data. The NHANES survey
samples are selected through a complex, multistage, probability design. The NHANES 2007–
2010 survey cycles oversampled major U.S. demographic subgroups and the study procedures
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are detailed in the references (20, 21). Informed consent was obtained from all participants and
the National Center for Health Statistics Research Ethics Review Board approved the protocol.
This study was based on analysis of publicly available NHANES 1988–1994 and 2007–
2010 spirometry data. During 1988–1994, 9616 persons aged 40–79 were interviewed, of these
8495 had both an interview and examination, and of these 7667 (79%) had valid spirometry [the
spirometry test met reliability/reproducibility quality control check (spprelia=1) and there were
two or more successful maneuvers (sppmaneu>1)] and height data, and were used in our study.
During 2007–2010, 7296 persons aged 40–79 years were interviewed and had a MEC
examination, and of these 7104 were eligible for spirometry. Of the 7104, 1281 participants
were excluded from spirometry for various reasons [safety reasons (649), limited time available
in the MEC (337), subject refusals (113), or other reasons (182)], and 346 had invalid spirometry
tests or missing height. Of those interviewed, 5476 (75%) had valid data and were included in
our study.
3.2.1

Spirometry
NHANES 2007–2010 spirometry testing was performed in accordance with

recommendations of the ATS (22) using Ohio 822/827 dry-rolling seal volume spirometers with
biological filters (A-M Systems PFT Filter Kit B) to minimize infection risks. These were the
same spirometers that were used in the NHANES III (1988–1994) spirometry testing. The
methods of spirometry measurements and the spirometry equipment were similar for both
surveys except for the following: 1) The spirometry software was slightly different with a
display of both the volume-time and flow-volume curves available for inspection by the
technician in 2007–2010 and provided immediate feedback to improve the quality of the tests;
only the flow-volume curve was displayed in 1988–1994, 2) NHANES III did not use in-line
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filters, 3) the minimum number of maneuvers performed per test session was three for NHANES
2007–2010 and five for NHANES 1988–1994, and 4) the 2007–2010 survey included new
annual refresher training and bi-weekly, as opposed to monthly, quality control reports by the
National Institute for Occupational Safety and Health (NIOSH).
In the 2007–2010 survey, participants whose test results indicated airflow obstruction
(FEV1/FVC < LLN or FEV1/FVC < 0.7) were selected for post-bronchodilator (post-BD)
spirometry. However, of the 1137 (20.8%) selected adults 40–79 years of age, only 577 (50.7%)
had the test done. Therefore, for comparison with NHANES 1988–1994, and because of the
relatively low participation in the post-BD testing, only the pre-BD spirometry was used in the
determination of the COPD prevalence. Nevertheless, the participants with the pre-BD and postBD spirometry in NHANES 2007–2010 were used to estimate the potential bias due to using
pre-BD tests in the estimation of COPD prevalence when applying the GOLD criteria.
Airflow obstruction definitions. Using the ATS criteria, mild or worse airflow obstruction was
defined as the ratio of FEV1 to FVC below the lower 5th percentile (i.e., LLN) (12). We
modified the GOLD Stage I criteria, mild or worse airflow obstruction to define it as pre-BD
FEV1/FVC < 0.7 (13). Moderate or worse airflow obstruction was defined as FEV1/FVC < LLN
plus FEV1 < 70% predicted based on the ATS criteria and as FEV1/FVC < 0.7 plus FEV1 < 80%
predicted based on the GOLD criteria. Severe airflow obstruction was defined as for moderate,
but using FEV1 < 50% predicted, for both ATS and GOLD. U.S. population reference equations
developed from NHANES III data were used to derive the predicted and LLN values for both
periods (23). Reference values are available for non-Hispanic white, non-Hispanic black, and
Mexican Americans. In this study, for the “other” race category, we applied a correction factor
of 0.88 to the corresponding values for non-Hispanic whites, which has been previously
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published as an adjustment factor for Asian participants. For the “other Hispanic” group, we
applied the predicted values for Mexican Americans.
Demographic variables of interest in this study for both time periods included gender,
self-reported age, self-reported race/ethnicity including non-Hispanic (NH) white, NH black, and
Mexican American, and self-reported education, self-reported smoking status, and calculated
body mass index (kg/m2). We also used the absence of self-reported respiratory symptoms of
chronic bronchitis and wheezing and health care provider diagnosed respiratory disease, to
identify “healthy nonsmokers”, i.e., individuals who did not report any of those conditions and
were nonsmokers.
3.2.2

Data analysis
The age-standardized prevalence was estimated using SAS®, version 9.2 software

procedure Proc SurveyReg (SAS Institute Inc. Cary, NC) (24) which accounted for the study
design (19) and NHANES MEC examination weights assigned to each individual. To make
estimates between the two time periods comparable with respect to the population age
distribution, estimates were age adjusted by the direct method using the year 2000 Census
Bureau projections for the U.S. civilian, non-institutionalized population using the following age
groups: 40-49, 50-59, 60-69 and 70-79 (20, 25). The weighted frequencies and means were
derived using SAS procedures Proc SurveyFreq and Proc SurveyMeans, both procedures
accounted for the study design and examination weights. To compare the prevalence estimates
from NHANES 1988–1994 and 2007–2010, we used the t-test and the Bonferroni adjustment of
the p-values to account for multiple comparisons within each categorical variable. To estimate
the burden of COPD for the U.S. population, the average U.S. population size for years 2007–
2010 was estimated using the national Current Population Survey (26) population size tables.
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To investigate the suitability of the NHANES III based reference equations for the 2007–
2010 data, we fit the NHANES III reference equations to a group of “healthy-nonsmokers” 20–
79 as defined above. For each person we calculated the predicted values for FEV1, FVC, and the
FEV1/FVC ratio based on the person’s ethnicity, age, height, and gender using the NHANES III
reference equations. Next, we calculated the standardized differences between the observed and
predicted values [i.e., z-score=(observed-predicted)/residual standard deviation]. The mean zscore and the lower 95% confidence limit were then plotted against categorized age, for adults 20
to 79 years of age and a t-test was used to test whether the mean z-score values differed
significantly from zero.
To estimate the percentage of those with COPD defined by GOLD Stage I criteria using
pre-BD spirometry and post-BD spirometry, we used the data for those participants who had
post-BD spirometry and calculated the unweighted percentage with COPD for pre-BD
spirometry and post-BD spirometry.
3.3

Results
Table 3.1 provides the descriptive statistics for the NHANES 1988–1994 and 2007–2010

participants aged 40–79 with valid spirometry and height, n=7667 and n=5476, respectively.
The two study samples were similar with respect to mean age (57.5 vs. 57.0 years) (data not
shown) and gender distribution. The 2007–2010 sample population had, however, a higher level
of education, where 47.6% had at least some college education or graduated vs. 27.2% in 1988–
1994. Also, the NHANES 2007–2010 sample had a higher proportion of never-smokers (49.6%
vs. 42.6%) and the combined categories of ex-smokers and current smokers showed a decrease in
mean pack-years of smoking (22.9 vs. 26.7). The prevalence of obesity (body mass index (BMI)
of 35 kg/m2 or greater) increased in 2007–2010 (15.4 vs. 10.0%).
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Table 3.2 shows the age-standardized prevalence of mild+ airflow obstruction by ATS
criteria (FEV1/FVC < LLN) for the 40–79 year olds. The overall prevalence decreased from
16.6% (SE 0.8) during 1988–1994 to 14.5% (SE 0.7) during 2007–2010. The 2007–2010
prevalence of mild+ airflow obstruction decreased for 60–69 years old, males, and Mexican
Americans also reached statistical significance.
Table 3.2 also shows the age-standardized prevalence of moderate+ airflow obstruction
defined as FEV1/FVC < LLN and FEV1 < 70% predicted. The overall prevalence dropped from
6.4% (SE 0.5) during 1988–1994 to 4.4% (SE 0.4) during 2007–2010. Again, the 2007–2010
prevalence was lower, reaching statistical significance for age category 60–69, both genders, NH
whites and Mexican Americans races, and higher education. Figure 3.1 shows the prevalence of
airflow obstruction (ATS and modified GOLD) by age categories by time period.
Table 3.2 also shows the age-standardized prevalence for severe airflow obstruction
based on the ATS criteria, for 40–79 year olds. The overall prevalence was 2.2% (SE 0.2) for
years 1988–1994 and 1.1% (SE 0.2) for 2007–2010. Often, the prevalence for the years 2007–
2010 was about half of the prevalence for 1988–1994 for the demographic factors.
Using the average U.S. population size for 40–79 years olds for years 2007–2010 of
126,199,000 and prevalence of ATS defined airflow obstruction of 14.5% for mild+, 4.4% for
moderate+, and 1.1% for severe degree, we estimated the number of individuals in the U.S. with
COPD. The burden of COPD is approximately 18.3 million with mild+ (95% CI 16.4–20.3), 5.6
million with moderate+ (95% CI 4.4–6.6) and 1.4 million with severe (95% CI 0.9–1.8).
Post-bronchodilator spirometry is required for the GOLD definition of COPD (9). In the
NHANES 2007–2010 study of the 5476 adults 40–79 years of age with valid spirometry, 1137
(20.8%) were selected for BD follow-up because their spirometry results indicated airflow
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obstruction. However, only 577 (50.7%) had the bronchodilator test done; 315 were not tested
because of safety reasons (such as uncontrolled blood pressure, irregular pulse on examination,
taking medication for major arrhythmia or certain other medications, implanted defibrillator, or
history of congenital heart disease) and 245 were not tested for other reasons (refusal,
insufficient time, and others). The group excluded for safety reasons had significantly (p<0.05)
lower mean FEV1/FVC ratio than those who had the post-BD test. The group excluded for other
than safety reasons did not differ statistically from those who had the post-BD test.
Nevertheless, of those with a post-BD test and pre-BD GOLD Stage I (549), only 354 (64.4%)
remained in the GOLD Stage I category after post-BD testing and 35.5% moved to normal.
To test how well the NHANES III reference values fit to the NHANES 2007–2010
sample population, we selected all “healthy” non-smokers 20–79 years of age from the
NHANES 2007–2010 data (n=1980). The mean standardized differences between the observed
and predicted values (z-score) were as follows: for FEV1 0.047 (SE 0.02; t=2.1; p<0.05), for
FVC 0.151 (SE 0.02; t=6.4; p<0.001), and for the FEV1/FVC ratio -0.188 (SE 0.02; t=-8.5;
p<0.001). The t-test values indicate that the observed mean z-scores were significantly different
from zero especially for FVC and the ratio. Figures 3.2-3.4 show the distribution of the z-scores,
the mean z-scores and their lower 95th percentile, by age categories. The mean z-scores were
close to zero for FEV1 for most age categories, but consistently above zero for FVC. The higher
z-score values for FVC reflect higher observed FVC values for the NHANES 2007–2010 sample
than was predicted based on the NHANES III based reference equations. The higher observed
FVC values then result in the lower mean FEV1/FVC values for NHANES 2007–2010, in
comparison to the predicted values derived from the NHANES III reference equations and thus a
negative z-score. The mean z-scores [(Observed-Predicted)/Relative Standard Deviation] are
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negative for most of the age categories since predicted FEV1/FVC values based on the NHANES
III data are higher than the observed mean FEV1/FVC values. Consequently, because the
distribution of the observed FEV1/FVC values is shifted towards zero with respect to the
predicted and LLN values, the LLN values derived from the NHANES III equations identified
more than 5% as being abnormal. Of the healthy non-smokers from the NHANES 2007–2010
sample, on average 7.4% were identified as having FEV1/FVC<LLN.
3.4

Discussion
We analyzed NHANES spirometry data from time periods 1988–1994 and 2007–2010 to

evaluate changes in the prevalence of airflow obstruction, a main feature of chronic obstructive
pulmonary disease, among older adults (age 40–79). Our results show that the ATS-defined
prevalence of airflow obstruction declined significantly from 16.6 to 14.5% (p< 0.05) for mild+
airflow obstruction categories as well as for the moderate+ airflow obstruction (6.4 vs. 4.4%,
p<0.01) categories. There was a statistically significant decline in the prevalence of airflow
obstruction in the age category 60–69 from 20.2 to 15.4% (p<0.01). In addition, the decline in
the prevalence of severe airflow obstruction was significant for current smokers. Reasons for the
decline in the estimated prevalence of airflow obstruction may include decrease in the prevalence
of smoking in the U.S. population, and reductions in occupational exposures and air pollution.
Although our study shows decline in the prevalence of airflow obstruction, lower
respiratory disease (primarily COPD) remains the third leading cause of death in the U.S. (27).
The high mortality rate from COPD may be explained by higher life expectancy and decreased
mortality from cardiovascular disease (27–30). Results from a recent Behavioral Risk Factors
Surveillance Survey (BRFSS) showed that the prevalence of self-reported doctor diagnosed
COPD increased systematically with age from 6.6% for the 45–54 year olds to 12.1% for the 65–
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74 year old U.S. adults for the year 2011 (4). The BRFSS prevalence of doctor-diagnosed
COPD of 12.1% for 65–74 year olds is lower than the prevalence of ATS defined mild+ airflow
obstruction of 14.4% for the 60–69 and 17.2% for the 70–79 age ranges observed in our study.
This difference may reflect different diagnostic methods other than spirometry results, i.e.
symptoms of chronic bronchitis or shortness of breath in the doctor-diagnosed COPD, medical
diagnosis of COPD without pulmonary function testing (31), or differences in the survey
methods. Nevertheless, the observed declining trend in the prevalence of airflow obstruction
based on spirometry measurements, as observed in our study, is likely to be reflected in declining
morbidity and mortality from COPD in the future if the trend in the decreasing exposure to
particulates continues (32, 33).
However, a previous study by Ford et al. reported no significant differences between
NHANES III and NHANES 2007–2010 sample populations in the prevalence of COPD (overall
prevalence 14.6% vs. 13.5%, p>0.05) (10) for ages 20–79 years using GOLD Stage I and II
criteria and pre-BD spirometry. Ford et al. estimated the prevalence of airflow obstruction at
29.4% in the 60–79 years age group. Ford et al. did not apply any reliability/reproducibility
criteria to the NHANES III data while our NHANES III analysis was limited to those with
reliable spirometry exams and at least 2 maneuvers, which may explain some of the differences
with our study. Our results also show that the differences in the prevalence of GOLD Stage I and
Stage II for the two time periods are not statistically significant, for most age categories (Figure
3.1). Using the GOLD criteria, Ford et al. estimates that in the larger U.S. population 20–79 age
group, 28.9 million have mild or more severe airflow obstruction based on GOLD Stage I, 12.9
million have moderate and more severe obstruction based on GOLD Stage II and 1.5 million
have severe airflow obstruction based on GOLD Stage III. Our estimate of the burden of COPD
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based on the prevalence of ATS-defined airflow obstruction, the main feature of COPD, for the
U.S. population 40–79 age group is approximately 18.3 (95% CI 16.4–20.3) million for mild+
airflow obstruction, 5.6 (95% CI 4.4–6.6) million for moderate+ airflow obstruction, and 1.4
(95% CI 0.9–1.8) million for severe airflow obstruction. Our estimate for the 40–79 age group
based on pre-BD criteria was approximately 25.2 (95% CI 22.3–27.8) million for GOLD Stage I
(mild+), 11.4 (95% CI 9.7–12.9) million for GOLD Stage II (moderate+), and 1.4 (95% CI 0.9–
1.9) million for GOLD stage III (severe). There are large differences between the modified
GOLD and ATS-based estimates for mild+ obstruction (25.2 vs. 18.3 million ≈ 6.9 million) and
for moderate+ obstruction (11.4 vs. 5.6 million ≈ 5.8 million).
Many publications have reported that the usage of fixed FEV1/FVC ratio criterion of 0.7,
especially when using pre-BD spirometry, leads to over estimation of the COPD prevalence in
older adults (15–18, 34, 35). The PLATINO study indicates that applying GOLD Stage I criteria
to pre-BD spirometry, rather than post-BD spirometry as required by GOLD recommendations,
may overestimate the COPD prevalence by approximately 35% (36). However, Tashkin et al.
(37) reported substantial acute bronchodilator reversibility in patients with early COPD who had
no other features of asthma suggesting that BD reversibility may not be a completely reliable
way of distinguishing asthma and COPD.
We have determined using the z-score analysis that usage of the NHANES III equations
may potentially lead to a slight overestimation of the prevalence of airflow obstruction in the
2007–2010 data. Although the reference equations fit well to the FEV1 data, FEV1 z-scores were
around zero, z-scores for FVC (i.e., for both the predicted and LLN values were systematically
above zero and above -1.645, respectively, for most age categories) and the mean z-score was
significantly higher than zero. As expected, the resulting z-score values for the ratio of
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FEV1/FVC were lower than zero for the predicted value and below -1.645 for the LLN values,
and the mean z-score was significantly lower than zero. This may be due to better spirometry
quality in the 2007–2010 testing period. Consequently, more “healthy never smokers” from
2007–2010 population sample were classified with airflow obstruction using the NHANES III
LLN criteria for the FEV1/FVC ratio (7.4%) rather than the expected 5%, potentially leading to
overestimation of the prevalence of airflow obstruction (Figure 3.5). This, in turn, likely
underestimates the true difference between the NHANES III and current NHANES estimates.
Limitations of the study include the exclusion of those participants who were unable to
perform spirometry including those on continuous daytime oxygen therapy in 2007–2010 (101 of
40–79 year olds). To investigate the potential effect of their exclusion on the estimated
prevalence, we added 44 of those that reported doctor-diagnosed emphysema and were excluded
from spirometry because they were on continuous daytime oxygen therapy into the airflow
obstruction group and recalculated the age-adjusted prevalence. Using ATS criteria, for 2007–
2010 and adding those additional cases, the overall prevalence of airflow obstruction increased
from 14.5 to 15.0%. The decline in prevalence between the two periods was no longer
statistically significant (p=0.075). Among the 60–69 year olds, inclusion of the emphysema
cases increased the prevalence from 15.4% to 16.0% for 2007–2010 and the decline from
NHANES III remained statistically significant (p<0.05). Generally, because of stringent
spirometry review of the flow-volume curves, it is unlikely that participants with airflow
obstruction would be excluded from these two studies due to invalid spirometry.
3.5

Conclusion
In conclusion, the prevalence of ATS-defined airflow obstruction decreased significantly

from 1988–1994 (16.6%) to 2007–2010 (14.5%), p<0.05 in the U.S. while prevalence rates are
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increasing worldwide. We estimated, based on the prevalence of ATS-defined airflow
obstruction, a main determinant of COPD, that approximately 18.3 million adults aged 40–79
have mild+ airflow obstruction, 5.6 million have moderate+ airflow obstruction, and 1.4 million
have severe airflow obstruction in the current U.S. population.
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Table 3.1. Descriptive statistics for NHANES 1988-1994 and NHANES 2007-2010 data (Unadjusted percentage of
selected characteristics of adults age 40-79 who had valid spirometry)
NHANES

Demographic data
NHANES 1988-1994
Sample
n

Population
N
(thousand)*

Frequency
Percent†

Overall
7,667
89,151
Age
40-49
2,408
33,187
31.4
50-59
1,719
21,999
22.4
60-69
2,042
20,100
26.6
70-79
1,498
13,864
19.5
Gender
Males
3,675
41,913
47.9
Females
3,992
47,237
52.1
Race
NH White
3,601
71,943
47.0
NH Black
1,972
8,608
25.7
Mexican American
1,800
3,162
23.5
Other Hispanic
--Other
294
3.8
Education
<High school grad
3,333
43.7
High school
2,218
29.1
Some college
1,035
13.6
College graduate
1,036
13.6
Body mass index
<30
5,332
69.4
≥30 – <35
1,551
20.1
≥35
774
10.0
Smoking status
Never smoker
3,268
42.6
Ex-smoker
2,511
32.8
Current smoker
1,888
24.6
Pack-years
(n, mean, (SE))
Ex-smoker +
4,280
26.7 (0.4)
current smoker
Current smoker
1,821
23.7 (0.5)
* Current Population Survey
† Age-weighted and age-standardized weighted prevalence
‡ Sample excludes those with missing values for height

NHANES 2007-2010
Sample‡
n

Population
N
(thousand)*

Frequency
Percent†

5,476

126,199

1,654
1,472
1,428
922

43,667
39,984
26,573
15,975

30.2
26.9
26.1
16.8

2,724
2,752

62,708
65,634

49.7
50.3

2,704
1,046
923
591
212

92,301
13,399
7,813

49.4
19.1
16.9
10.8
3.9

1,569
1,293
1,435
1,173

28.7
23.6
26.2
21.4

3,474
1,106
834

64.2
20.4
15.4

2,714
1,643
1,117

49.6
30.0
20.4

2,659

22.9 (0.5)

1,100

25.9 (0.8)
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Table 3.2. Age-standardized prevalence of ATS defined mild+ (FEV1/FVC<LLN); moderate+ (FEV1/FVC<LLN and
FEV1<70%); and severe airflow obstruction (FEV1/FVC<LLN and FEV1<50%) among U.S. adults aged 40-79 years, by
periods 1988-1994 and 2007-2010
NHANES

Overall
Age
40-49
50-59
60-69
70-79
Gender
Males
Females
Race
NH White
NH Black
Mexican American
Education
<High school grad
High school grad
Some college
College graduate
Smoking status
Never smoker
Ex-smoker
Current smoker

Mild+ airflow obstruction

Moderate+ airflow obstruction

1988-94

2007-10

T-test of
Difference

1988-94

2007-10

P† (SE)
16.6 (0.8)

P† (SE)
14.5 (0.7)

p-value
*

P† (SE)
6.4 (0.5)

P† (SE)
4.4 (0.4)

12.8 (1.0)
16.6 (1.2)
20.2 (1.2)
22.1 (1.6)

12.7 (0.9)
15.2 (1.7)
15.4 (1.3)
17.2 (1.5)

3.0 (0.6)
6.2 (0.7)
10.0 (1.0)
11.0 (1.2)

2.3 (0.6)
4.5 (0.6)
5.8 (0.7)
7.8 (1.0)

19.0 (1.1)
14.6 (0.9)

15.4 (0.9)
13.8 (1.0)

6.8 (0.5)
6.1 (0.6)

4.5 (0.5)
4.2 (0.4)

17.3 (0.8)
15.9 (1.0)
12.7 (0.8)

15.9 (0.8)
13.6 (1.2)
8.4 (0.8)

6.7 (0.5)
5.8 (0.7)
3.7 (0.6)

4.7 (0.5)
4.7 (0.7)
1.7 (0.3)

18.3 (1.4)
17.2 (1.1)
16.6 (1.3)
12.9 (1.5)

15.3 (1.3)
17.6 (1.6)
15.0 (1.1)
10.9 (1.3)

7.7 (0.8)
7.7 (0.8)
6.3 (0.8)
2.7 (0.6)

6.6 (1.1)
5.9 (0.6)
3.7 (0.6)
2.3 (0.5)

8.0 (0.8)
16.2 (1.0)
31.8 (1.3)

8.2 (0.8)
14.5 (1.3)
34.4 (1.8)

1.9 (0.4)
6.0 (0.7)
14.9 (1.0)

1.1 (0.2)
4.5 (0.7)
14.9 (1.3)

**

**

***

†Age-specific and age-standardized weighted prevalence
*p < 0.05; **p < 0.01; ***p < 0.001; after Bonferroni adjustment
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Severe airflow obstruction

T-test of
Differen
ce
p-value
**

1988-94

2007-10

T-test of
Difference

P† (SE)
2.2 (0.2)

P† (SE)
1.1 (0.2)

p-value
***

1.0 (0.3)
2.0 (0.3)
4.1 (0.6)
3.6 (0.8)

0.3 (0.2)
1.1 (0.3)
1.7 (0.6)
2.3 (0.5)

**
**

2.4 (0.3)
2.2 (0.3)

1.1 (0.3)
1.0 (0.2)

**
**

**

2.5 (0.3)
1.5 (0.3)
0.8 (0.2)

1.0 (0.2)
1.8 (0.5)
0.6 (0.3)

***

2.9 (0.5)
2.2 (0.4)
3.1 (0.7)
0.6 (0.3)

2.0 (0.5)
1.6 (0.4)
0.9 (0.3)
0.1 (0.1)

0.7 (0.2)
1.8 (0.3)
5.8 (0.7)

0.3 (0.1)
1.1 (0.3)
3.4 (0.7)

**

*

**

**

**

*

45

40

35

Prevalence

30

Age

25

40-49
50-59

20

60-69
70-79

15

10

5

0
1988-94

2007-10

ATS Mild+

1988-94

2007-10

1988-94

2007-10

GOLD Stage I*

ATS Moderate+

1988-94

2007-10

GOLD Stage II*

Figure 3.1. Prevalence of airflow obstruction by severity, by age category, by time period. ATS
Mild+: any airflow obstruction; ATS Moderate+: Moderate and severe airflow obstruction.
*Modified GOLD criteria
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Figure 3.2. Z-score for FEV1 by age; -1.645 line is the lower limit of normal – 5th percentile;
Short dashed line connects the mean z-score for each age category in relation to zero;
Long dashed line connects the mean LLN for each age category
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Figure 3.3. Z-score for FVC by age; -1.645 line is the lower limit of normal – 5th percentile;
Short dashed line connects the mean z-score for each age category in relation to zero;
Long dashed line connects the mean LLN for each age category
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Figure 3.4. Z-score for ratio by age; -1.645 line is the lower limit of normal – 5th percentile;
Short dashed line connects the mean z-score for each age category in relation to zero;
Long dashed line connects the mean LLN for each age category
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Chapter 4
Prevalence of Chronic Obstructive Pulmonary Disease among U.S. Working
Adults Aged 40–70 Years: National Health Interview Survey Data 2004–2001
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4.1

Introduction
Chronic obstructive pulmonary disease (COPD) is a primary cause of morbidity and

mortality globally (1). In the U.S., COPD ranks third in causes of mortality with 100,000 deaths
annually. An estimated 15.0 million people had healthcare provider diagnosed COPD in 2010,
and an estimated 12.0 million potential cases were undiagnosed (2–4). The estimated total
annual cost of COPD for 2010 was $49.9 billion (5). The probability of being employed is
reduced by 8.6% with COPD associated disability (4).
COPD is a chronic disease usually more prevalent among older adults (6, 7). Balmes et
al. (8) concluded that 15% of COPD is attributable to occupational exposure. Furthermore
according to Bang et al. (9) certain occupation groups have higher prevalence of COPD,
especially among services occupations. Therefore for the current study we analyzed data for
working adults aged 40–70 years by occupation. This study is based on the most recently
available National Health Interview Survey (NHIS) data (2004–2011) for COPD by occupation,
representing a large sample of U.S. working adults. The aim of our study was to 1) estimate the
prevalence of COPD among older working adults in the United States by major occupational
groups, and 2) provide prevalence odds ratios (PORs) of COPD by major occupational groups.
4.2 Methods
The NHIS is an annual cross-sectional survey of the non-institutionalized U.S. population
conducted by the National Center for Health Statistics of the Centers for Disease Control and
Prevention (10). The NHIS survey samples are selected through a complex, multistage,
probability design and the data are collected through personal interviews of participants aged
≥18 years. Informed consent was obtained from all participants and the National Center for
Health Statistics Research Ethics Review Board approved the protocol. For our study, we
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included years 2004–2011. Eight years of data were combined to improve the precision and
reliability of the estimates. The survey response rate for the NHIS adults sampled ranged from
72.5% in 2004 to 66.3% in 2011. Questionnaires, documentation, and datasets are publicly
available at
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2011/srvydesc.pdf`
During years 2004-2011, of the 141 million estimated U.S. working adults 18 years and
older, an estimated 73.8 million were 40–70 years of age. Currently working adults were defined
as those who were employed during the week prior to their interview. We defined COPD based
on a positive response to one or both questions:
Have you EVER been told by a doctor or other health professional that you had ...Emphysema?
DURING THE PAST 12 MONTHS, have you been told by a doctor or other health professional
that you had ...Chronic bronchitis?
Demographic data were collected during the interview including self-reported age,
gender, smoking status, and race; race was categorized as White, Black, and other. Information
on each participant’s current employment by industry and occupation was gathered and recoded
by the National Center for Health Statistics (NCHS) for confidentiality reasons. Our study
included the recoded 23 major occupation groups, which were based on Census Occupation
Codes as reported by Standard Occupation Classification (SOC) codes (10). Participants with
unknown and missing information for COPD were excluded from analysis. The occupation
codes prior to 2004 are not directly comparable to the more recent data because of the changes in
coding in 2004. Therefore, we analyzed 2004–2011 NHIS data (11).
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4.2.1

Data Analysis
We estimated COPD prevalence for individuals aged 40–70 years for 2004–2011, by

demographic characteristics, smoking status, and current occupation. SAS® 9.3 (SAS Institute
Inc., Cary, NC) (12) software was used to analyze data and calculate estimated frequencies,
standard errors, and prevalence rates with 95% confidence intervals (CIs). We used a logistic
regression model to estimate prevalence odds ratios (PORs) by occupation. We chose
management occupations as a reference group because we perceived that they have low
likelihood of occupational exposure to agents that could contribute to COPD and because they
were previously reported to have minimal risk of COPD (9). The overall models were adjusted
for smoking status (current, former, never), age, gender, race, and pack-years of cigarette
smoking (available for current smokers only). Models were also stratified by smoking status and
never smoker estimates were presented.
4.3

Results

4.3.1

Overall COPD Prevalence and Prevalence by Occupational Categories
The overall COPD prevalence estimates, by gender, by race, and by education level are

provided in Table 4.1. The estimated overall COPD prevalence for working adults aged 40-70
years was 4.18% (95% CI 4.01–4.34). Prevalence of COPD was higher among females (5.40%,
95% CI 5.12–5.67) and Whites (4.40%, 95% CI 4.22–4.59).
Among major occupational groups, the estimated prevalence of COPD was highest in
healthcare support (7.11%, 95% CI 5.64–8.57), especially among females (7.70%, 95% CI 6.08–
9.33) and Whites (8.42%, 95% CI 6.43–10.41) (Table 4.2). Food preparation and serving related
occupations (6.46%, 95% CI 5.12–7.80) had the next highest COPD prevalence overall, again
primarily among females (8.41%, 95% CI 6.52–10.31) and Whites (7.31%, 95% CI 5.59–9.03).
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COPD prevalence among personal care and service (5.28%, 95% CI 4.14–6.42) is also of interest
with higher odds in females (5.67%, 95% CI 4.39–6.94), Whites (5.67%, 95% CI 4.25–7.09) and
Blacks (5.62%, 95% CI 3.06–8.18).
4.3.2 COPD Prevalence Odds Ratios by Occupational Categories as Compared with
Management Occupations
Occupations that had significantly elevated associations with COPD included healthcare
support (POR = 1.64, 95% CI 1.25–2.14); food preparation and serving (POR = 1.57, 95% CI
1.20–2.06); installation, maintenance, and repair (POR = 1.52, 95% CI 1.16–1.98); protective
service (POR = 1.5, 95% CI 1.07–2.11); building and grounds cleaning and maintenance support
(POR = 1.4, 95% CI 1.08–1.81); and office and administrative support (POR = 1.25, 95% CI
1.04–1.51).
Among never smokers, occupations associated with COPD included food preparation and
serving (POR = 2.34, 95% CI 1.52–3.60); protective service (POR = 2.11, 95% CI 1.27–3.49);
office and administrative support (POR = 1.51, 95% CI 1.11–2.07); and education, training, and
library (POR = 1.44, 95% CI 1.05–1.98).
Occupations with significant PORs differed by gender. Females had elevated PORs
among workers in protective services (POR = 2.12, 95% CI 1.31–3.42); food preparation and
serving (POR = 1.72, 95% CI 1.25–2.37); healthcare support (POR = 1.70, 95% CI 1.24–2.33);
and office and administrative support (POR = 1.34, 95% CI 1.06–1.70). In contrast, the only
significant PORs for males were among education, training, and library (POR = 1.79, 95% CI
1.17–2.75); building and grounds cleaning and maintenance (POR = 1.68, 95% CI 1.17–2.42);
and installation, maintenance, and repair (POR = 1.41, 95% CI 1.04–1.93).
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Results from the race-specific analyses identified Whites as the subgroup with higher risk
of COPD (Table 4.3). There were significantly elevated associations of occupation with COPD
among workers in health care support (POR = 1.80, 95% CI 1.33–2.44); food preparation and
serving (POR = 1.61, 95% CI 1.20–2.18); protective service (POR = 1.57, 95% CI 1.08–2.30);
installation, maintenance, and repair (POR = 1.53, 95% CI 1.14–2.03); building and grounds
cleaning and maintenance support (POR = 1.41, 95% CI 1.07–1.85); transportation and material
moving (POR = 1.36, 95% CI 1.01–1.84); construction and extraction (POR = 1.35, 95% CI
1.00–1.81); office and administrative support (POR = 1.31, 95% CI 1.07–1.60) and education
training and library (POR = 1.28, 95% CI 1.01–1.62).
4.4

Discussion
During 2004–2011, the overall prevalence of self-reported doctor-diagnosed COPD

among working adults aged 40–70 years was 4.18% and increased with age from 3.75% for 40–
54 to 5.13% for 55–70 years old. COPD prevalence was higher among females, Whites, and
current smokers which was consistent with previous findings (9). Results from a study using
Behavioral Risk Factor Surveillance System (BRFSS) data showed that the prevalence of selfreported doctor-diagnosed COPD (or chronic bronchitis or emphysema) among all U.S. adults
increased with age from 6.6% for adults age 45–54 to 12.1% for those age 65–74 for the year
2011 (2). However, overall prevalence of COPD in our study among working adults was lower
than the BRFSS estimates that would include non-working individuals with COPD associated
disability.
The COPD prevalence estimates vary by occupation. As compared with overall working
adults, workers in services occupations including healthcare support, food preparation and
serving, and personal care and service occupations had higher COPD prevalence in our study and
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that of Bang et al. (9). Various factors have been associated with COPD and smoking is one of
the most important risk factors (2, 13, 14). Smoking prevalence estimates among the above
listed service occupations were 20% or higher and exceeded the Healthy People 2020 goal of ≤
12% (13, 15). The prevalence of COPD for current smokers in comparison to never smokers
was 5.7 times higher for personal care and service, 3.7 times higher for the healthcare support
occupation, and 2.5 times for protective service. Generally, smoking and occupational exposures
have been shown to have an interactive effect on an additive scale on COPD (14).
It has been estimated that 15% of COPD is attributable to occupational exposure (8).
Vapors, gas, dust and fume exposures have been shown to be associated with COPD among
workers in various occupations and industries (9, 16–20). Exposure to organic dust and other
sensitizing agents in agricultural and food workers can lead to respiratory conditions including
COPD (21). Among construction workers, exposure to inorganic dust may lead to higher COPD
morbidity and mortality (22). Yet COPD prevalence among construction and agriculture was not
as high as the overall working population, probably because of the selected age groups and the
fact that the mean age in construction was 39 years for the overall working population (mean age
not included in tables) and results were based on the current job in an older population where
study participants likely had prior jobs that are not reflected in the analysis. Chronic exposure to
coal and silica dust increases risk of COPD in miners (8, 23).
COPD prevalence estimates also varied by gender. Overall, females had higher
prevalence than males which is consistent with findings reported by Ford et al. (24). Various
factors have been associated with COPD among women, some of which are smoking,
environmental tobacco smoke, biological differences, occupational exposure, or a combination
of all these factors (25, 26). In our study, females employed in protective service; food
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preparation and serving; production; and transportation and material moving had COPD
prevalence estimates that were two to four times higher than males. This is consistent with a
previous study by Bang et al. (9) and a review publication by Varkey (27).
As compared to management occupations, the odds of having COPD were significantly
higher among all workers in healthcare support; protective service; food preparation and serving
related; building and grounds cleaning and maintenance; and installation, maintenance, and
repair even after adjustment. This is also consistent with studies by Bang et al. (9) and Hnizdo et
al. (28).
This study has some limitations. Disease classification and subsequent prevalence rates
were based on self-reports of health care professional diagnosed emphysema and/or chronic
bronchitis. Although spirometry may have been used in the COPD diagnosis, spirometry
information was not collected in the NHIS study. Self-report of COPD is prone to recall bias.
Chronic bronchitis may be confused with acute bronchitis and this may have resulted in
misclassification (29). Additionally, some of the gender-related differences we found where
females had higher prevalence of COPD may be due to higher likelihood of females visiting a
doctor. In our analysis, we adjusted for smoking status (current, former smoker, never smoker)
and for pack-years of cigarette smoking among current smokers. However, the data did not
contain information to allow us to adjust for pack-years among former smokers. In addition, the
cross-sectional study design has limitations for determining causality; the current job may not be
the one that contributed to COPD, and may be affected by the presence of disease and the
management reference group may be populated with individuals who had previous, higher
exposure jobs.
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Information detailing occupational history on the type of jobs held was not collected and
was limited to employment in the week prior to the interview, considering latency, the job with
causal exposure may not be reflected in the analysis. However Gomez-Marin et al. (30)
concluded that for many occupational subgroups, the current occupation may represent the
longest-held job. No information on occupational exposures was collected. We restricted our
study to those aged 40–70 years to estimate COPD in the older age groups when the onset of
COPD is more likely to occur. The cutoff of 70 years was used with the assumption that workers
could have changed to a job with less exposure.
4.5

Conclusion
The present study conducted from 2004–2011 represents the most recently available data

on COPD prevalence in the U.S. working population and among specific occupational
categories. Prevalence estimates varied by occupation suggesting that workplace exposures in
addition to different smoking habits may contribute to the COPD risk. Preventive measures such
as reduction of occupational exposure (14) and interventions to reduce smoking may reduce the
prevalence of COPD (31). Healthcare providers should continue screening and surveillance for
work-related COPD and epidemiologic studies are needed to monitor changes in COPD
prevalence among workers in at risk occupations and industries.
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Table 4.1. Estimated number of U.S. working adults (40–70 years) and
prevalence of self-reported physician diagnosed COPD by
selected characteristics, 2004–2011
Characteristic

N†

COPD
P*

95% CI

Age
40 - 54
50,825
3.75
55 - 70
22,974
5.13
Gender
Male
38,739
3.07
Female
35,060
5.40
Race
White
61,952
4.40
Black
7,762
3.41
Other
4,086
2.15
Smoking status
73,799
Current
14,220
7.47
Former
17,933
4.92
Never
41,024
2.74
Unknown/missing
622
Total
73,799
4.18
†Annual average estimates are per 1,000 population
P* Prevalence Estimates
- Prevalence estimates not calculated for missing or
unknown values
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3.54–3.95
4.76–5.49
2.85–3.28
5.12–5.67
4.22–4.59
2.98–3.83
1.65–2.66
6.96–7.97
4.50–5.33
2.54–2.94
4.01–4.34

Table 4.2. Estimated prevalence of COPD, by occupation, gender, and race — U.S. working adults 40–70 years, 2004–2011
Overall
Males
Females
Occupation
COPD
COPD
COPD
N†
95% CI
N†
95 % CI
N†
95 % CI
P*
P*
P*
Management
Business and financial
operations
Computer and mathematical
Architecture and engineering
Life, physical, and social
science
Community and social
services
Legal
Education, training, and
library
Arts, design, entertainment,
sports, and media
Healthcare practitioners and
technical
Healthcare support
Protective service
Food preparation and serving
related
Building and grounds
cleaning and maintenance
Personal care and service
Sales and related
Office and administrative
support
Farming, fishing, and forestry
Construction and extraction
Installation, maintenance,
and repair
Production
Transportation and material
moving
Military
Refused, not ascertained,
don’t know
Total

Whites
COPD
P*

N†

95 % CI

N†

Blacks
COPD
P*

95 % CI

8,440

3.22

2.75–3.68

5,465

2.64

2.08–3.19

2,975

4.29

3.45–5.13

7,548

3.22

2.74–3.71

489

4.43

2.15–6.71

3,358

3.58

2.82–4.35

1,575

1.83

0.95–2.71

1,782

5.13

3.92–6.34

2,837

3.61

2.77–4.45

308

4.38

1.98–6.77

1,742

2.61

1.68–3.54

1,215

2.51

1.39–3.63

527

2.84

1.29–4.38

1,460

2.68

1.64–3.73

130

-

-

1,546

1.88

1.05–2.72

1,368

1.50

0.72–2.28

178

-

-

1,355

1.98

1.04–2.91

51

-

-

730

3.03

1.59–4.47

407

-

-

323

4.78

2.26–7.31

632

3.18

1.57–4.80

32

-

-

1,294

3.97

2.87–5.06

533

3.52

1.45–5.58

761

4.28

2.89–5.67

999

4.11

2.83–5.39

235

-

-

958

3.65

2.34–4.96

510

-

-

448

4.73

2.62–6.84

866

3.62

2.21–5.02

62

-

-

4,887

4.50

3.79–5.22

1,175

4.14

2.71–5.57

3,712

4.62

3.78–5.46

4,302

4.66

3.86–5.45

436

3.96

2.11–5.81

1,282

3.95

2.59–5.31

648

3.71

1.83–5.59

634

4.19

2.23–6.15

1,160

3.54

2.18–4.90

67

-

-

4,067

3.82

3.10–4.54

1,056

2.82

1.59–4.06

3,011

4.17

3.32–5.02

3,334

4.11

3.29–4.94

423

3.46

1.37–5.54

1,442

7.11

5.64–8.57

170

-

-

1,272

7.70

6.08–9.33

994

8.42

6.43–10.41

367

4.47

2.65–6.29

1,345

4.45

3.18–5.71

1,056

3.18

1.91–4.46

289

9.05

5.63–12.48

1,047

4.86

3.29–6.43

249

3.06

1.48–4.63

2,221

6.46

5.12–7.80

718

2.39

1.23–3.54

1,502

8.41

6.52–10.31

1,652

7.31

5.59–9.03

370

4.56

2.50–6.62

3,069

4.86

4.01–5.72

1,699

4.32

3.15–5.50

1,369

5.53

4.10–6.97

2,424

5.23

4.23–6.24

488

3.43

1.95–4.91

2,088

5.28

4.14–6.42

368

-

-

1,719

5.67

4.39–6.94

1,590

5.67

4.25–7.09

311

5.62

3.06–8.18

6,916

3.93

3.37–4.50

3,694

2.98

2.21–3.75

3,222

5.02

4.20–5.84

6,076

4.26

3.62–4.90

442

-

-

9,690

5.32

4.76–5.89

2,131

2.96

1.99–3.93

7,559

5.99

5.32–6.65

8,160

5.66

5.01–6.31

4.16

2.87–5.46

428

3.43

1.51–5.34

320

-

-

108

-

-

369

3.44

1.37–5.52

1,093
28

-

-

3,822

3.91

3.08–4.73

3,701

3.81

2.97–4.64

121

-

-

3,394

4.20

3.29–5.12

315

-

-

2,830

4.31

3.42–5.20

2,714

3.98

3.09–4.87

116

-

-

2,457

4.46

3.45–5.48

240

-

-

5,032

4.01

3.40–4.62

3,421

3.00

2.31–3.70

1,611

6.15

4.82–7.48

4,112

4.41

3.67–5.15

591

3.07

1.76–4.39

4,306

4.41

3.54–5.28

3,501

3.75

2.91–4.59

805

7.25

4.37–10.13

3,439

4.88

3.80–5.97

685

1.78

0.82–2.73

85

-

-

51

-

-

35

-

-

60

-

-

16

-

-

2,222

1.79

2.91–4.59

1,242

1.01

0.43–1.59

980

2.78

1.68–3.88

1,686

1.81

1.12–2.49

334

-

-

73,799

4.18

4.01–4.34

38,739

3.07

2.85–3.28

35,060

5.40

5.12–5.67

61,952

4.40

4.22–4.59

7,762

3.406

2.98–3.83

†Estimated annual average per 1,000 working population
- Relative standard errors greater than 30% are not reported
P* Prevalence estimates
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Table 4.3. Adjusted COPD prevalence odds ratios POR by occupation for specific groups — U.S. working adults 40–70 years, 2004–2011

Occupation

POR

Overall
95% CI

Never Smokers
POR
95% CI

POR

POR

POR

1.00

Whites
95% CI

1.00

Business and financial operations

1.01

0.77–1.33

1.25

0.83–1.89

0.72

0.42–1.22

1.21

0.87–1.67

1.00

0.74–1.34

Computer and mathematical

0.95

0.63–1.44

0.95

0.57–1.59

1.11

0.67–1.84

0.73

0.39–1.35

0.96

0.61–1.50

Architecture and engineering

0.70

0.43–1.14

-

-

0.57

0.32–1.02

-

-

0.72

0.43–1.21

Life, physical, and social science

0.91

0.54–1.53

-

-

-

-

1.16

0.63–2.11

0.93

0.53–1.64

Community and social services

1.15

0.82–1.59

1.35

0.79–2.30

1.59

0.83–3.06

1.02

0.69–1.51

1.15

0.80–1.66

Legal

1.13

0.76–1.66

1.10

0.60–2.01

-

-

1.13

0.69–1.86

1.12

0.73–1.71

Education, training, and library

1.23

0.98–1.54

1.44

1.05–1.98

1.79

1.17–2.75

1.18

0.89–1.56

1.28

1.01–1.62

1.13

0.77–1.66

1.11

0.59–2.07

1.46

0.82–2.58

0.97

0.57–1.65

1.01

0.66–1.54

1.02

0.79–1.32

1.34

0.92–1.96

1.27

0.76–2.11

1.03

0.76–1.39

1.07

0.82–1.41

Healthcare support

1.64

1.25–2.14

1.57

0.98–2.49

-

-

1.70

1.24–2.33

1.80

1.33–2.44

Protective service

1.50

1.07–2.11

2.11

1.27–3.49

1.21

0.76–1.93

2.12

1.31–3.42

1.57

1.08–2.30

1.57

1.20–2.06

2.34

1.52–3.60

1.08

0.62–1.87

1.72

1.25–2.37

1.61

1.20–2.18

1.40

1.08–1.81

1.55

0.99–2.43

1.68

1.17–2.42

1.19

0.82–1.72

1.41

1.07–1.85

Personal care and service

1.25

0.94–1.66

0.96

0.61–1.52

1.41

0.57–3.49

1.26

0.91–1.73

1.24

0.90–1.70

Sales and related

1.05

0.84–1.33

1.41

0.97–2.04

1.07

0.74–1.55

1.06

0.80–1.40

1.13

0.89–1.44

Office and administrative support

1.25

1.04–1.51

1.51

1.11–2.07

1.08

0.72–1.62

1.34

1.06–1.70

1.31

1.07–1.60

Farming, fishing, and forestry

1.17

0.64–2.13

-

-

-

-

-

-

1.09

0.58–2.08

Food preparation and serving
related
Building and grounds cleaning and
maintenance

1.00

Females
95% CI

Management

Arts, design, entertainment, sports,
and media
Healthcare practitioners and
technical

1.00

Males
95% CI

1.00

Construction and extraction

1.29

0.97–1.71

-

-

1.29

0.93–1.79

-

-

1.35

1.00–1.81

Installation, maintenance, and repair

1.52

1.16–1.98

1.34

0.74–2.43

1.41

1.04–1.93

-

-

1.53

1.14–2.03

Production

1.17

0.94–1.46

1.21

0.84–1.74

1.05

0.77–1.42

1.32

0.96–1.81

1.22

0.97–1.55

Transportation and material moving

1.30

0.99–1.71

1.53

0.90–2.62

1.26

0.90–1.77

1.48

0.90–2.42

1.36

1.01–1.84

Refused, not ascertained, don’t know
Military was excluded from analysis because of relative standard errors > 30%
Overall adjusted for age, gender, race, smoking status, and pack-years
Never Smokers adjusted for age, gender, and race
Gender adjusted for age, race, smoking status, and pack-years
Whites adjusted for age, gender, smoking status, and pack-years
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Chapter 5
5.1 Summary
Chronic obstructive pulmonary disease (COPD) is a preventable disease that causes
excess morbidity and mortality in older populations (1). A primary risk factor is tobacco
smoking, but occupational exposure to VGDF also contributes to the burden of the disease. The
goal of this study was to gain additional understanding about occupational risk factors for COPD
by using data from three population-based cross-sectional studies. The three studies were used
to explore different aspects of the relationship between COPD and occupational exposure, and
each study provides additional insight into the understanding of COPD and contributed to the
overall goal of the study. The three studies are detailed in Chapters 2–4. Chapter 2 incorporates
the objectives of both Aim 1 and Aim 2. Aim 1 involves developing a generalizable job exposure
matrix (JEM) for COPD. Aim 2 involves applying the JEM to a population based study, in this
case the Multi-Ethnic Study of Atherosclerosis (MESA) lung study, to establish an association
between COPD and occupational exposure. Aim 3 of the study (Chapters 3 and 4) was
addressed through estimating prevalence of COPD in the U.S. population and its major
occupational groups. Chapter 3 reports on the prevalence of airflow obstruction based on
spirometry and compared the prevalence for two sampling periods 1988–1994 and 2007–2010 of
the National Health and Nutrition Examination Surveys (NHANES). Chapter 4 reports on the
prevalence of COPD for major occupational groups based on self-report of doctor-diagnosed
chronic bronchitis or emphysema for years 2004–2011 using the National Health Interview
Survey (NHIS) data.
In the MESA study (Chapter 2), an expanded JEM for COPD was created based upon the
methodology used by Blanc et al. (2) for an overall general VGDF exposure classification for
detailed occupational groups. The JEM provided an assessment of VGDF exposure for overall
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dust exposure, and subcategories of mineral dust and organic dust, vapor-gas, and fumes, in
terms of the potential level of exposure (low, medium and high) as assigned by industrial
hygiene experts. The JEM was then applied to estimate an association between potential
occupation exposure levels and various COPD outcomes. Adjusted odds ratios were
significantly increased for the association of airflow limitation with the high level of overall dust
exposure, especially among males, and organic dust exposure for females. Adjusted odds ratios
were also significantly increased for the association of airflow limitation with self-report of
severe VGDF exposure, vapor-gas exposure, and exposure all three VGDF agents (vapor-gas,
dust, and fumes). Self-report of physician diagnosis of COPD was associated with self-report of
dust, vapor-gas, severity of VGDF exposure, years of VGDF exposure, and number of VGDF
agents. Self-report of Medical Research Council defined chronic bronchitis (3) was associated
with the self-reported VGDF exposures listed above for COPD and additionally with exposure to
dust and fumes (see Tables 2.2, 2.4, 2.5, Chapter 2).
In general, the significant associations of COPD, chronic bronchitis, and wheeze with
occupational exposure were stronger among never smokers. The association of airflow
limitation with the interaction of smoking and occupational exposures was investigated. Never
smokers with no occupational exposure were used as the reference group. There was an
increasing trend in odds ratios including the last category of ever smokers with occupational
exposure (a similar trend was found by Blanc et al. (2)). Our study adds to the knowledge and
understanding of the association of COPD with VGDF exposure ascertained both through a
COPD JEM and VGDF exposure questions (Tables 2.2 – 2.5, Chapter 2).
Study 2 (Chapter 3) provided the prevalence of COPD in the U.S population as
determined by spirometry defined airflow obstruction and compared the study periods in
NHANES 1988–1994 to NHANES 2007–2010. Overall, the prevalence of airflow obstruction
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declined from 1988–1994 to 2007–2010. The prevalence of airflow obstruction significantly
declined from 16.6% in 1988–1994 to 14.5% in 2007–2010. Moderate or worse airflow
obstruction declined from 6.4% in 1988–1994 to 4.4% 2007–2010.
Study 3 (Chapter 4) was based on the NHIS data for years 2004–2011. Overall estimated
prevalence of self-reported COPD (bronchitis and emphysema) was 4.18% and the estimated
COPD prevalence for major occupational groups ranged from 7.11% for healthcare support to
1.88% for architecture and engineering. The occupation groups greater than the national average
were healthcare support (7.11%); food preparation and serving (6.46%); office and
administrative support (5.32%); personal care and service (5.28%); building and grounds
cleaning and maintenance (4.86%); education, training, and library (4.5%); protective service
(4.45%); transportation and material moving (4.41%); and installation, maintenance, and repair
(4.31%). Females and Whites had the highest COPD prevalence.
Study 3 also estimated prevalence odds ratios (POR) for major occupational groups using
management as a reference group. The adjusted PORs that reached statistical significance were
healthcare support (POR=1.64, 95% CI 1.25–2.14), food preparation and serving (POR=1.57,
95% CI 1.20–2.06), installation, maintenance, and repair (POR=1.52, 95% CI 1.16–1.98),
protective service (POR=1.50, 95% CI 1.07–2.11), building and grounds cleaning and
maintenance (POR=1.40, 95% CI 1.08–1.81), and office and administrative support (POR=1.25,
95% CI 1.04–2.51). These results are consistent with results found by Bang et al. (4) when
evaluating NHIS 1997–2004 data.
Service occupations with higher COPD prevalence also had higher smoking prevalence,
which is a major risk factor for COPD. The prevalence of COPD among current smokers in
service occupations (protective service; healthcare support; and personal care and service) was
2.5 – 5.7 times greater than that of never smokers. CDC authors reported prevalence of current
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cigarette smoking as 16.4% among protective service workers, 23.7% among healthcare support
workers, and 19.7% among personal care and service workers (5).
Never smokers were also investigated for COPD prevalence because stratification by
smoking status would eliminate smoking as a confounder. Among never smokers, significant
PORs for COPD were highest in food preparation and serving related occupations (POR = 2.34)
followed by protective service (POR 1.5), office and administrative support occupations (POR =
1.51), and education, training and library occupations (POR = 1.44). Odds of COPD were
significantly elevated for most of these occupational groups where VGDF exposure risks are
often present.
5.2

Significance
The goal and focus of this study was to investigate the prevalence of COPD outcomes in

several cross-sectional studies and estimate their association with occupational risk factors such
as vapors-gas, dust or fumes (VGDF), or the association with occupational categories. Included
in the goal was to develop and test a job exposure matrix for COPD outcomes. COPD was
assessed using good quality spirometry as an objective measure. Important COPD outcome
associations were found with VGDF exposures. Exposure to noxious respirable agents in
combination with smoking can result in COPD occurrence with unusual severity and/or
frequency (6). An important confirmation that smoking and exposure to VGDF had increased
odds of COPD compared to never smokers not exposed was found in this study.
5.3

Strengths and Limitations
A major strength of this study is that we used three large study populations.

Additionally, the MESA study was designed to heavily sample minority groups, and NHANES
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and NHIS were both large U.S. population based cross-sectional samples. NHIS had a large
working population. MESA contained 3-digit occupation codes (coded by NIOSH) and provided
detailed information about employment (and allowing the application of the COPD JEM).
NHANES and MESA both had spirometry on a large number of individuals so that we could
determine those with airflow obstruction. NHIS had occupational coding (although only at the
2-digit level) to allow comparison of occupational groups and to make prevalence estimates. A
JEM for COPD was created and applied to the MESA study. The JEM, along with self-report of
occupational exposure to VGDF helped us better understand occupational exposure.
A limitation of the MESA data was the lack of information about the longest held job and
the COPD JEM could only be applied to the last job the worker held. The non-availability of
NHANES 3-digit occupational codes to apply the COPD JEM was another limitation. However,
NIOSH is working with NHANES National Center for Health Statistics scientists to provide the
codes. NHIS and NHANES are both publically available only in 2-digit occupational codes
which limit the ability to assess COPD risk through application of a COPD JEM. The
generalizable JEM will be made publicly available and also in the future will be applied to the
three-digit occupational codes for NHANES studies developed by NIOSH.
Self-report of health care provider diagnosed COPD based on emphysema or chronic
bronchitis was available through NHIS. There was no spirometry performed as a part of NHIS
which may have provided a more objective measure. However, spirometry may have been part
of the COPD diagnosis. In the survey, acute bronchitis may have been misclassified as chronic
bronchitis (7). COPD self-report may also be susceptible to recall bias.
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5.4

Future Research
Future research should involve refining the COPD job exposure matrix and improving

our 3-digit JEM (participants also have an occupational history) and investigating the feasibility
of using a 2-digit COPD JEM. Also we plan to apply the COPD JEM to NHANES 3-digit
occupational data that was coded by NIOSH and make the JEM available to the public. Our
proposed study for the application of our JEM to the MESA CT scans providing the percentage
with emphysema for over 6400 participants has been approved by the MESA committee.
5.5

Conclusion
The prevalence COPD is increasing globally and it has broad public health impacts. Our

results indicate that the prevalence of COPD in the U.S. is declining; however it still remains the
third leading cause of mortality. The odds of COPD are significantly higher among those
exposed to VGDF.
In the first study, significant associations were found between the prevalence of airflow
limitation and occupational exposure determined by self-reported exposure and JEM assigned
scores. There was an indication of an increased risk of COPD when both smoking and VGDF
exposures were present. We developed an expanded COPD JEM for use in future studies.
Chronic bronchitis and wheeze each were associated with self-reported exposures (vapor-gas,
dust, fumes, and VGDF exposure severity, years of exposure, and number of agents).
In the second study, the prevalence of ATS-defined airflow obstruction decreased
significantly from 1988–1994 to 2007–2010. The study provided estimates of approximately
18.3 million adults aged 40–79 with mild+ airflow obstruction, 5.6 million with moderate+
airflow obstruction, and 1.4 million with severe airflow obstruction in the current U.S.
population.
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The third study conducted from 2004–2011 presents COPD prevalence in the U.S.
working population and among specific occupational categories. Prevalence estimates varied by
occupation suggesting that workplace exposures in addition to different smoking habits may
contribute to the COPD risk. The occupations with the highest PORs included healthcare
support; food preparation and serving; installation, maintenance, and repair; protective service;
and building and grounds cleaning and maintenance all of which have potentially significant
exposures to VGDF.
The three studies described in this project were population based studies which help
provide direction for worker health surveillance. Lewis and Fishwick (8) provided an in-depth
review of health surveillance for occupational respiratory disease. With respect to COPD, the
objectives of health surveillance include quantification of the exposure health risk, identification
of groups at risk for COPD, collection of COPD epidemiological data, and early detection of
COPD so that the worker could be removed from the exposure or the exposure could be
controlled. Fishwick et al. (9) investigated the causation of COPD by workplace exposures. It is
important to determine how much of COPD is caused by workplace exposure on the working
population level and the individual level for disease prevention and obtaining workers’
compensation. COPD experts and occupational lung disease experts provided occupational
contribution ratings for COPD cases with varying combinations of smoking exposures and
occupational exposure from employment history based on hypothetical cases of COPD. The
clinical raters from their occupational attribution of COPD causation made recommendations
about a change of work or continuation of work in the same job. Guidotti (10) discussed the
workers’ compensation challenges and the new requirements in California to adopt evidencebased criteria for impairment assessment and treatment through apportionment by cause. The
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results of our research can better inform the health care provider about COPD in the population
and the VGDF exposures to better assess the occupation contribution to COPD.
Preventive measures such as reduction of occupational exposure (2) through engineering
controls, administrative controls, and an adequate respiratory protection program and
interventions to reduce smoking such as smoking cessation programs may reduce the prevalence
of COPD (11). COPD screening and surveillance by healthcare providers of workers exposed to
VGDF should be provided to increase the awareness among workers and epidemiologic studies
are needed to track changes in the COPD prevalence among workers in at risk occupations and
inform workers and employers in high risk occupations to increase awareness and target
preventions. Based on the results of our study and literature review some recommendations for
future actions with regard to workers’ COPD prevention include more resources for prevention;
increasing worker participation in prevention, surveillance, and VGDF exposure reduction
programs; equipping health care professionals’ with additional skills in determining VGDF
occupational exposure hazards and COPD diagnosis (10).
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